WO2019112630A1 - Peptide compositions for slowing degradation of vitamin-mineral supplements, foods, pharmaceuticals, and cosmetics - Google Patents
Peptide compositions for slowing degradation of vitamin-mineral supplements, foods, pharmaceuticals, and cosmetics Download PDFInfo
- Publication number
- WO2019112630A1 WO2019112630A1 PCT/US2018/000390 US2018000390W WO2019112630A1 WO 2019112630 A1 WO2019112630 A1 WO 2019112630A1 US 2018000390 W US2018000390 W US 2018000390W WO 2019112630 A1 WO2019112630 A1 WO 2019112630A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- asp
- peptides
- composition
- peptide
- vitamin
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 221
- 239000000203 mixture Substances 0.000 title claims abstract description 115
- 230000015556 catabolic process Effects 0.000 title claims abstract description 54
- 238000006731 degradation reaction Methods 0.000 title claims abstract description 54
- 235000013305 food Nutrition 0.000 title claims abstract description 43
- 239000002537 cosmetic Substances 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title claims description 17
- 229940029985 mineral supplement Drugs 0.000 title abstract description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 97
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 82
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 69
- 239000010949 copper Substances 0.000 claims abstract description 66
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 63
- 229910052802 copper Inorganic materials 0.000 claims abstract description 63
- 229910052751 metal Inorganic materials 0.000 claims abstract description 41
- 239000002184 metal Substances 0.000 claims abstract description 41
- 229910052742 iron Inorganic materials 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 34
- 229940088594 vitamin Drugs 0.000 claims abstract description 33
- 229930003231 vitamin Natural products 0.000 claims abstract description 33
- 239000011782 vitamin Substances 0.000 claims abstract description 33
- 235000013343 vitamin Nutrition 0.000 claims abstract description 31
- 230000000699 topical effect Effects 0.000 claims abstract description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 122
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 58
- 235000015097 nutrients Nutrition 0.000 claims description 53
- 150000003839 salts Chemical class 0.000 claims description 50
- 235000010323 ascorbic acid Nutrition 0.000 claims description 49
- 239000011668 ascorbic acid Substances 0.000 claims description 49
- 239000011707 mineral Substances 0.000 claims description 48
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 47
- VPSHHQXIWLGVDD-ZLUOBGJFSA-N Asp-Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VPSHHQXIWLGVDD-ZLUOBGJFSA-N 0.000 claims description 44
- 229960005070 ascorbic acid Drugs 0.000 claims description 32
- 235000019152 folic acid Nutrition 0.000 claims description 32
- 239000011724 folic acid Substances 0.000 claims description 32
- -1 cofactors Substances 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 31
- 235000001014 amino acid Nutrition 0.000 claims description 23
- 150000001413 amino acids Chemical class 0.000 claims description 23
- 239000003826 tablet Substances 0.000 claims description 19
- 235000010755 mineral Nutrition 0.000 claims description 18
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 16
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 16
- 239000011734 sodium Substances 0.000 claims description 15
- 229910052708 sodium Inorganic materials 0.000 claims description 15
- 239000011575 calcium Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- 235000019157 thiamine Nutrition 0.000 claims description 14
- 239000011721 thiamine Substances 0.000 claims description 14
- 125000000539 amino acid group Chemical group 0.000 claims description 13
- 229960003495 thiamine Drugs 0.000 claims description 13
- 229910052791 calcium Inorganic materials 0.000 claims description 12
- 239000011777 magnesium Substances 0.000 claims description 12
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 12
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 11
- 235000003704 aspartic acid Nutrition 0.000 claims description 11
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 11
- 230000003247 decreasing effect Effects 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 229910052749 magnesium Inorganic materials 0.000 claims description 11
- 230000007423 decrease Effects 0.000 claims description 10
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 9
- FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 claims description 9
- 108010040443 aspartyl-aspartic acid Proteins 0.000 claims description 9
- 230000008859 change Effects 0.000 claims description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- 229930003779 Vitamin B12 Natural products 0.000 claims description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 8
- 238000000354 decomposition reaction Methods 0.000 claims description 8
- 235000018102 proteins Nutrition 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 235000019163 vitamin B12 Nutrition 0.000 claims description 8
- 239000011715 vitamin B12 Substances 0.000 claims description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 7
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229940014144 folate Drugs 0.000 claims description 6
- 238000010348 incorporation Methods 0.000 claims description 6
- 239000011591 potassium Substances 0.000 claims description 6
- 229910052700 potassium Inorganic materials 0.000 claims description 6
- WXERCAHAIKMTKX-ZLUOBGJFSA-N Ala-Asp-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O WXERCAHAIKMTKX-ZLUOBGJFSA-N 0.000 claims description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 5
- 238000009506 drug dissolution testing Methods 0.000 claims description 5
- 239000011785 micronutrient Substances 0.000 claims description 5
- 235000013369 micronutrients Nutrition 0.000 claims description 5
- OZRFYUJEXYKQDV-UHFFFAOYSA-N 2-[[2-[[2-[(2-amino-3-carboxypropanoyl)amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]butanedioic acid Chemical compound OC(=O)CC(N)C(=O)NC(CC(O)=O)C(=O)NC(CC(O)=O)C(=O)NC(CC(O)=O)C(O)=O OZRFYUJEXYKQDV-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 4
- 235000019155 vitamin A Nutrition 0.000 claims description 4
- 239000011719 vitamin A Substances 0.000 claims description 4
- 229940045997 vitamin a Drugs 0.000 claims description 4
- WCFCYFDBMNFSPA-ACZMJKKPSA-N Asp-Asp-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O WCFCYFDBMNFSPA-ACZMJKKPSA-N 0.000 claims description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 3
- 229930003316 Vitamin D Natural products 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 229930003448 Vitamin K Natural products 0.000 claims description 3
- 229910052804 chromium Inorganic materials 0.000 claims description 3
- 239000011651 chromium Substances 0.000 claims description 3
- 230000000593 degrading effect Effects 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 235000019166 vitamin D Nutrition 0.000 claims description 3
- 239000011710 vitamin D Substances 0.000 claims description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 235000019168 vitamin K Nutrition 0.000 claims description 3
- 239000011712 vitamin K Substances 0.000 claims description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 3
- 229940046008 vitamin d Drugs 0.000 claims description 3
- 229940046010 vitamin k Drugs 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- JPHYJQHPILOKHC-ACZMJKKPSA-N Glu-Asp-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O JPHYJQHPILOKHC-ACZMJKKPSA-N 0.000 claims description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000007894 caplet Substances 0.000 claims description 2
- 235000015111 chews Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 229940126534 drug product Drugs 0.000 claims description 2
- 230000037406 food intake Effects 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 229910052748 manganese Inorganic materials 0.000 claims description 2
- 239000011572 manganese Substances 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000004381 Choline salt Substances 0.000 claims 3
- 235000019417 choline salt Nutrition 0.000 claims 3
- 150000003248 quinolines Chemical class 0.000 claims 3
- 239000008247 solid mixture Substances 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 239000012535 impurity Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 126
- 229940009098 aspartate Drugs 0.000 abstract description 64
- 229910052723 transition metal Inorganic materials 0.000 abstract description 23
- 150000003624 transition metals Chemical class 0.000 abstract description 23
- 229940126701 oral medication Drugs 0.000 abstract description 20
- 150000002739 metals Chemical class 0.000 abstract description 19
- 150000003722 vitamin derivatives Chemical class 0.000 abstract description 18
- 235000020786 mineral supplement Nutrition 0.000 abstract description 6
- 239000000470 constituent Substances 0.000 abstract description 4
- 230000001079 digestive effect Effects 0.000 abstract description 3
- 239000003755 preservative agent Substances 0.000 abstract description 3
- 235000015872 dietary supplement Nutrition 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 235000019195 vitamin supplement Nutrition 0.000 abstract description 2
- 239000002253 acid Substances 0.000 description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 52
- 238000004090 dissolution Methods 0.000 description 39
- 235000002639 sodium chloride Nutrition 0.000 description 33
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 26
- 229960000304 folic acid Drugs 0.000 description 26
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 229940024606 amino acid Drugs 0.000 description 21
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 19
- 239000000463 material Substances 0.000 description 19
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 18
- 239000002609 medium Substances 0.000 description 18
- 229940072107 ascorbate Drugs 0.000 description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 229910052760 oxygen Inorganic materials 0.000 description 15
- 239000001301 oxygen Substances 0.000 description 15
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 14
- 238000007254 oxidation reaction Methods 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 13
- 235000007635 levomefolic acid Nutrition 0.000 description 13
- 239000011578 levomefolic acid Substances 0.000 description 13
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 12
- 229930003268 Vitamin C Natural products 0.000 description 12
- 230000008901 benefit Effects 0.000 description 12
- 239000008108 microcrystalline cellulose Substances 0.000 description 12
- 229940016286 microcrystalline cellulose Drugs 0.000 description 12
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 12
- 230000003647 oxidation Effects 0.000 description 12
- 229940083542 sodium Drugs 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 235000019154 vitamin C Nutrition 0.000 description 12
- 239000011718 vitamin C Substances 0.000 description 12
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 11
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 229960005261 aspartic acid Drugs 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 238000002390 rotary evaporation Methods 0.000 description 10
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 229910052786 argon Inorganic materials 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- 229960004643 cupric oxide Drugs 0.000 description 8
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 239000012298 atmosphere Substances 0.000 description 7
- 230000036284 oxygen consumption Effects 0.000 description 7
- 239000013589 supplement Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000007987 MES buffer Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 229960002885 histidine Drugs 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000002453 shampoo Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 235000013734 beta-carotene Nutrition 0.000 description 4
- 239000011648 beta-carotene Substances 0.000 description 4
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 4
- 229960002747 betacarotene Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 235000010216 calcium carbonate Nutrition 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 235000000639 cyanocobalamin Nutrition 0.000 description 4
- 239000011666 cyanocobalamin Substances 0.000 description 4
- 229960002104 cyanocobalamin Drugs 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 235000018977 lysine Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 3
- 244000045195 Cicer arietinum Species 0.000 description 3
- 235000010523 Cicer arietinum Nutrition 0.000 description 3
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 3
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
- GADGMZDHLQLZRI-VIFPVBQESA-N N-(4-aminobenzoyl)-L-glutamic acid Chemical group NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 GADGMZDHLQLZRI-VIFPVBQESA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 244000061456 Solanum tuberosum Species 0.000 description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000008452 baby food Nutrition 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 3
- 239000000920 calcium hydroxide Substances 0.000 description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 3
- VAFAEQCKZBKRLZ-CEOVSRFSSA-L calcium;(2s)-2-aminobutanedioate;hydron Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CC(O)=O.[O-]C(=O)[C@@H](N)CC(O)=O VAFAEQCKZBKRLZ-CEOVSRFSSA-L 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 239000012738 dissolution medium Substances 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000011261 inert gas Substances 0.000 description 3
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 3
- 239000000347 magnesium hydroxide Substances 0.000 description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 235000010746 mayonnaise Nutrition 0.000 description 3
- 239000008268 mayonnaise Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000010525 oxidative degradation reaction Methods 0.000 description 3
- 235000020957 pantothenol Nutrition 0.000 description 3
- 239000011619 pantothenol Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 3
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 3
- 235000014438 salad dressings Nutrition 0.000 description 3
- 235000015067 sauces Nutrition 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 3
- 229960005055 sodium ascorbate Drugs 0.000 description 3
- 235000010378 sodium ascorbate Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 3
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 2
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 2
- SOHLZANWVLCPHK-LBPRGKRZSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxo-4-phenylmethoxybutanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC(=O)OCC1=CC=CC=C1 SOHLZANWVLCPHK-LBPRGKRZSA-N 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 2
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- NAPNAGZWHQHZLG-ZLUOBGJFSA-N Asp-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)N NAPNAGZWHQHZLG-ZLUOBGJFSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000237519 Bivalvia Species 0.000 description 2
- 235000009025 Carya illinoensis Nutrition 0.000 description 2
- 244000068645 Carya illinoensis Species 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 240000004713 Pisum sativum Species 0.000 description 2
- 235000010582 Pisum sativum Nutrition 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 240000001417 Vigna umbellata Species 0.000 description 2
- 235000011453 Vigna umbellata Nutrition 0.000 description 2
- 235000010722 Vigna unguiculata Nutrition 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 2
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229930014669 anthocyanidin Natural products 0.000 description 2
- 235000008758 anthocyanidins Nutrition 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 235000013793 astaxanthin Nutrition 0.000 description 2
- 239000001168 astaxanthin Substances 0.000 description 2
- 229940022405 astaxanthin Drugs 0.000 description 2
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- JMNIIIQOMSQWJN-ACGFUFEJSA-L calcium;(4s)-4-[[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate Chemical compound [Ca+2].C1NC=2N=C(N)NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1.C1NC=2N=C(N)NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1 JMNIIIQOMSQWJN-ACGFUFEJSA-L 0.000 description 2
- 235000012174 carbonated soft drink Nutrition 0.000 description 2
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 150000001765 catechin Chemical class 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 235000020639 clam Nutrition 0.000 description 2
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 2
- 235000006279 cobamamide Nutrition 0.000 description 2
- 239000011789 cobamamide Substances 0.000 description 2
- ZIHHMGTYZOSFRC-UWWAPWIJSA-M cobamamide Chemical compound C1(/[C@](C)(CCC(=O)NC[C@H](C)OP(O)(=O)OC2[C@H]([C@H](O[C@@H]2CO)N2C3=CC(C)=C(C)C=C3N=C2)O)[C@@H](CC(N)=O)[C@]2(N1[Co+]C[C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C3=NC=NC(N)=C3N=C1)O)[H])=C(C)\C([C@H](C/1(C)C)CCC(N)=O)=N\C\1=C/C([C@H]([C@@]\1(CC(N)=O)C)CCC(N)=O)=N/C/1=C(C)\C1=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]1CCC(N)=O ZIHHMGTYZOSFRC-UWWAPWIJSA-M 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 235000015071 dressings Nutrition 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 229960002089 ferrous chloride Drugs 0.000 description 2
- 239000011773 ferrous fumarate Substances 0.000 description 2
- 235000002332 ferrous fumarate Nutrition 0.000 description 2
- 229960000225 ferrous fumarate Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 159000000011 group IA salts Chemical class 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000012680 lutein Nutrition 0.000 description 2
- 239000001656 lutein Substances 0.000 description 2
- 229960005375 lutein Drugs 0.000 description 2
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 2
- 235000012661 lycopene Nutrition 0.000 description 2
- 239000001751 lycopene Substances 0.000 description 2
- 229960004999 lycopene Drugs 0.000 description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 235000012245 magnesium oxide Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000007672 methylcobalamin Nutrition 0.000 description 2
- 239000011585 methylcobalamin Substances 0.000 description 2
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 2
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 2
- 229940101267 panthenol Drugs 0.000 description 2
- 229940023735 panthenyl ethyl ether Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000011772 phylloquinone Substances 0.000 description 2
- 235000019175 phylloquinone Nutrition 0.000 description 2
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 2
- 229960001898 phytomenadione Drugs 0.000 description 2
- 235000021574 pickled cabbage Nutrition 0.000 description 2
- 235000021573 pickled cucumbers Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 235000012029 potato salad Nutrition 0.000 description 2
- 235000019814 powdered cellulose Nutrition 0.000 description 2
- 229920003124 powdered cellulose Polymers 0.000 description 2
- 229920002414 procyanidin Polymers 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 235000013930 proline Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000006479 redox reaction Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 229960000342 retinol acetate Drugs 0.000 description 2
- 239000011770 retinyl acetate Substances 0.000 description 2
- 235000019173 retinyl acetate Nutrition 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 235000019141 sandwich spread Nutrition 0.000 description 2
- 229940055619 selenocysteine Drugs 0.000 description 2
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 2
- 235000016491 selenocysteine Nutrition 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229940045999 vitamin b 12 Drugs 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 2
- 235000010930 zeaxanthin Nutrition 0.000 description 2
- 239000001775 zeaxanthin Substances 0.000 description 2
- 229940043269 zeaxanthin Drugs 0.000 description 2
- COMUWNFVTWKSDT-SSDOTTSWSA-N (2,5-dioxopyrrolidin-1-yl) (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C)C(=O)ON1C(=O)CCC1=O COMUWNFVTWKSDT-SSDOTTSWSA-N 0.000 description 1
- YBEPDTOTOCUWHF-REOHCLBHSA-N (2r)-2-(phosphonoamino)-3-sulfanylpropanoic acid Chemical compound OC(=O)[C@H](CS)NP(O)(O)=O YBEPDTOTOCUWHF-REOHCLBHSA-N 0.000 description 1
- NVFHUBRALOJXMJ-REOHCLBHSA-N (2s)-2-(phosphonoamino)butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NP(O)(O)=O NVFHUBRALOJXMJ-REOHCLBHSA-N 0.000 description 1
- KKGSCLRYTMKKLP-VKHMYHEASA-N (2s)-2-(phosphonoamino)pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NP(O)(O)=O KKGSCLRYTMKKLP-VKHMYHEASA-N 0.000 description 1
- KKPUODLFBBWJPH-DKWTVANSSA-L (2s)-2-aminobutanedioate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)[C@@H](N)CC([O-])=O KKPUODLFBBWJPH-DKWTVANSSA-L 0.000 description 1
- VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- AUFGTPPARQZWDO-YPMHNXCESA-N 10-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)N(C=O)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 AUFGTPPARQZWDO-YPMHNXCESA-N 0.000 description 1
- GIPOFCXYHMWROH-UHFFFAOYSA-L 2-aminoacetate;iron(2+) Chemical compound [Fe+2].NCC([O-])=O.NCC([O-])=O GIPOFCXYHMWROH-UHFFFAOYSA-L 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 description 1
- KJKIIUAXZGLUND-UHFFFAOYSA-N 25-Hydroxyergocalciferol Natural products C1CCC2(C)C(C(C=CC(C)C(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C KJKIIUAXZGLUND-UHFFFAOYSA-N 0.000 description 1
- 239000003872 25-hydroxy-cholecalciferol Substances 0.000 description 1
- KJKIIUAXZGLUND-ICCVIKJNSA-N 25-hydroxyvitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C KJKIIUAXZGLUND-ICCVIKJNSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
- MEANFMOQMXYMCT-OLZOCXBDSA-N 5,10-methenyltetrahydrofolic acid Chemical compound C([C@H]1CNC2=C([N+]1=C1)C(=O)N=C(N2)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C([O-])=O)C=C1 MEANFMOQMXYMCT-OLZOCXBDSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 1
- YCWUVLPMLLBDCU-UHFFFAOYSA-N 5-Formiminotetrahydrofolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=N)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 YCWUVLPMLLBDCU-UHFFFAOYSA-N 0.000 description 1
- 229940105150 5-methyltetrahydrofolic acid Drugs 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- AKPLMZMNJGNUKT-ZLUOBGJFSA-N Asp-Asp-Cys Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O AKPLMZMNJGNUKT-ZLUOBGJFSA-N 0.000 description 1
- VHWNKSJHQFZJTH-FXQIFTODSA-N Asp-Asp-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)N VHWNKSJHQFZJTH-FXQIFTODSA-N 0.000 description 1
- XAJRHVUUVUPFQL-ACZMJKKPSA-N Asp-Glu-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O XAJRHVUUVUPFQL-ACZMJKKPSA-N 0.000 description 1
- 125000006847 BOC protecting group Chemical group 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- RNWQBKPFVUEQIG-UHFFFAOYSA-N CN1C(=O)N(C)C(=O)C2=C1N=C(O)N2C.CN1C(=O)N(C)C(=O)C2=C1N=C(O)N2C Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=C(O)N2C.CN1C(=O)N(C)C(=O)C2=C1N=C(O)N2C RNWQBKPFVUEQIG-UHFFFAOYSA-N 0.000 description 1
- 235000021318 Calcifediol Nutrition 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 102100039250 Essential MCU regulator, mitochondrial Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000005955 Ferric phosphate Substances 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- FUTAPPOITCCWTH-WHFBIAKZSA-N Gly-Asp-Asp Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O FUTAPPOITCCWTH-WHFBIAKZSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- MVADCDSCFTXCBT-CIUDSAMLSA-N His-Asp-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MVADCDSCFTXCBT-CIUDSAMLSA-N 0.000 description 1
- 101000813097 Homo sapiens Essential MCU regulator, mitochondrial Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ZFOMKMMPBOQKMC-KXUCPTDWSA-N L-pyrrolysine Chemical compound C[C@@H]1CC=N[C@H]1C(=O)NCCCC[C@H]([NH3+])C([O-])=O ZFOMKMMPBOQKMC-KXUCPTDWSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000000556 Paullinia cupana Nutrition 0.000 description 1
- 240000003444 Paullinia cupana Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- WYHIICXRPHEJKI-UHFFFAOYSA-N Trientine hydrochloride Chemical compound Cl.Cl.NCCNCCNCCN WYHIICXRPHEJKI-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 229930003761 Vitamin B9 Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- HLMUYZYLPUHSNV-NTISSMGPSA-N [(2s)-1,4-dioxo-1,4-bis(phenylmethoxy)butan-2-yl]azanium;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C([C@H](N)C(=O)OCC=1C=CC=CC=1)C(=O)OCC1=CC=CC=C1 HLMUYZYLPUHSNV-NTISSMGPSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000003214 anti-biofilm Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 238000005574 benzylation reaction Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000012745 brilliant blue FCF Nutrition 0.000 description 1
- MDXRFOWKIZPNTA-UHFFFAOYSA-L butanedioate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)CCC([O-])=O MDXRFOWKIZPNTA-UHFFFAOYSA-L 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 description 1
- HAUBPZADNMBYMB-UHFFFAOYSA-N calcium copper Chemical compound [Ca].[Cu] HAUBPZADNMBYMB-UHFFFAOYSA-N 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- NEUSVAOJNUQRTM-UHFFFAOYSA-N cetylpyridinium Chemical compound CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NEUSVAOJNUQRTM-UHFFFAOYSA-N 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960005443 chloroxylenol Drugs 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229940105778 coagulation factor viii Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- VVYPIVJZLVJPGU-UHFFFAOYSA-L copper;2-aminoacetate Chemical compound [Cu+2].NCC([O-])=O.NCC([O-])=O VVYPIVJZLVJPGU-UHFFFAOYSA-L 0.000 description 1
- ZZBHLLYRFXFBLC-UHFFFAOYSA-N copper;decanedioic acid Chemical compound [Cu].OC(=O)CCCCCCCCC(O)=O ZZBHLLYRFXFBLC-UHFFFAOYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940076286 cupric acetate Drugs 0.000 description 1
- 239000011641 cupric citrate Substances 0.000 description 1
- 235000019855 cupric citrate Nutrition 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229940124448 dermatologic drug Drugs 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 108091007735 digestive proteases Proteins 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940032958 ferric phosphate Drugs 0.000 description 1
- 229960002583 ferrous aspartate Drugs 0.000 description 1
- 229940086413 ferrous bisglycinate Drugs 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 229960001604 ferrous succinate Drugs 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 1
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 229940013640 flavin mononucleotide Drugs 0.000 description 1
- 239000011768 flavin mononucleotide Substances 0.000 description 1
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002410 histidine derivatives Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 235000021129 infant diet Nutrition 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- WBJZTOZJJYAKHQ-UHFFFAOYSA-K iron(3+) phosphate Chemical compound [Fe+3].[O-]P([O-])([O-])=O WBJZTOZJJYAKHQ-UHFFFAOYSA-K 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229910000399 iron(III) phosphate Inorganic materials 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 230000003050 macronutrient Effects 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000000695 menaquinone group Chemical group 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QCAWEPFNJXQPAN-UHFFFAOYSA-N methoxyfenozide Chemical compound COC1=CC=CC(C(=O)NN(C(=O)C=2C=C(C)C=C(C)C=2)C(C)(C)C)=C1C QCAWEPFNJXQPAN-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 235000020772 multivitamin supplement Nutrition 0.000 description 1
- 229940049292 n-(3-(dimethylamino)propyl)octadecanamide Drugs 0.000 description 1
- WWVIUVHFPSALDO-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCCN(C)C WWVIUVHFPSALDO-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000020956 nicotinamide riboside Nutrition 0.000 description 1
- 239000011618 nicotinamide riboside Substances 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108010082406 peptide permease Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical class [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- FDIKHVQUPVCJFA-UHFFFAOYSA-N phosphohistidine Chemical compound OP(=O)(O)NC(C(=O)O)CC1=CN=CN1 FDIKHVQUPVCJFA-UHFFFAOYSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 238000000252 photodiode array detection Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229960003548 polymyxin b sulfate Drugs 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- WHOMFKWHIQZTHY-UHFFFAOYSA-L pyridoxine 5'-phosphate(2-) Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(CO)=C1O WHOMFKWHIQZTHY-UHFFFAOYSA-L 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000020945 retinal Nutrition 0.000 description 1
- 239000011604 retinal Substances 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 239000008257 shaving cream Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229960004029 silicic acid Drugs 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 229940057950 sodium laureth sulfate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940048842 sodium xylenesulfonate Drugs 0.000 description 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 235000012756 tartrazine Nutrition 0.000 description 1
- 239000004149 tartrazine Substances 0.000 description 1
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 1
- 229960000943 tartrazine Drugs 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CPAQTOOVJUGQJV-UBMJGTQTSA-J tetrapotassium (2S)-2-aminobutanedioate Chemical compound N[C@@H](CC(=O)[O-])C(=O)[O-].N[C@@H](CC(=O)[O-])C(=O)[O-].[K+].[K+].[K+].[K+] CPAQTOOVJUGQJV-UBMJGTQTSA-J 0.000 description 1
- 235000019191 thiamine mononitrate Nutrition 0.000 description 1
- 239000011748 thiamine mononitrate Substances 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 229960004860 thiamine mononitrate Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- STDMRMREKPZQFJ-UHFFFAOYSA-H tricopper;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Cu+2].[Cu+2].[Cu+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O STDMRMREKPZQFJ-UHFFFAOYSA-H 0.000 description 1
- 235000021081 unsaturated fats Nutrition 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000019159 vitamin B9 Nutrition 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 150000003772 α-tocopherols Chemical class 0.000 description 1
- 235000019145 α-tocotrienol Nutrition 0.000 description 1
- 150000003773 α-tocotrienols Chemical class 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 150000003781 β-tocopherols Chemical class 0.000 description 1
- 235000019151 β-tocotrienol Nutrition 0.000 description 1
- 150000003782 β-tocotrienols Chemical class 0.000 description 1
- 150000003785 γ-tocopherols Chemical class 0.000 description 1
- 235000019150 γ-tocotrienol Nutrition 0.000 description 1
- 150000003786 γ-tocotrienols Chemical class 0.000 description 1
- 150000003789 δ-tocopherols Chemical class 0.000 description 1
- 235000019144 δ-tocotrienol Nutrition 0.000 description 1
- 150000003790 δ-tocotrienols Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C07K5/06113—Asp- or Asn-amino acid
- C07K5/06121—Asp- or Asn-amino acid the second amino acid being aromatic or cycloaliphatic
- C07K5/0613—Aspartame
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C07K5/06113—Asp- or Asn-amino acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
Definitions
- the present technology is related to peptide compositions for slowing the degradation of vitamin-mineral supplements, foods, pharmaceuticals, and cosmetics, as well as methods of making and using such compositions.
- the present peptide compositions include short two to five residue peptides having at least two aspartic acid residues.
- multivitamin-mineral preparations include several minerals that are transition metals having multiple oxidation states such as iron, copper, chromium, and manganese. It has been recognized for many decades that such metals are capable of degrading various vitamins and other nutrients. For example, the presence of copper has been shown to increase the rate of vitamin B12 degradation [Kondo, H et al, J Clin Invest. 1982 70(4):889-98.].
- transition metals such as iron and copper, are well known to catalyze the oxidation of ascorbic acid
- cupric oxide has extremely low bioavailability [Baker DH. Cupric oxide should not be used as a copper supplement for either animals or humans. J Nutr. 1999 129(12):2278-9]. Although many multivitamin-mineral supplements are formulated with cupric oxide, this does not provide the copper needed by humans or animals. It is apparent that manufacturers include this ineffective form in order to avoid the destruction of the other product components as demonstrated above.
- EDTA ethylenediamine tetraacetic acid
- EDTA ethylenediamine tetraacetic acid
- rancidity disagreeable odor or taste of decomposing oils or fats
- This chelating agent has a very high affinity for many metals, and is considered to be safe for use in certain foods within concentration ranges specified by the FDA and other national regulatory agencies. It is also used in topical or oral drugs, and cosmetics.
- EDTA also has antimicrobial and antibiofilm activities. Moreover, it potentiates other antimicrobials for example those used in wound care.
- Non-biodegradable chelating agents such as EDTA also increase the difficulty of metal removal from waste streams.
- Small peptides containing two or more aspartic acid residues have been discovered that slow the degradation of vitamins and other nutrients, especially in vitamin- mineral supplements, of foods, topical or oral drugs, and of cosmetics.
- the peptide or peptides can be premixed with metal or metals as salts, or added to the final product separately from the metals, or both.
- An advantage of small peptides over traditional chelators is that the small peptides can be hydrolyzed by digestive proteases, thus releasing the metal(s) for subsequent absorption.
- these peptides are biodegradable.
- Degradation can be slowed by a composition comprising an effective amount of one or more peptides or a pharmaceutically acceptable salt thereof, wherein each peptide has two to five amino acid residues and at least two of the residues are aspartic acid residues; one or more physiologically acceptable minerals or other physiologically acceptable agents capable of degrading one or more nutrients or drugs; and one or more nutrients and/or drugs sensitive to degradation by the physiologically acceptable minerals or other physiologically acceptable agents; wherein the one or more peptides preferably do not contain histidine.
- a composition comprising an effective amount of one or more peptides or a pharmaceutically acceptable salt thereof, wherein each peptide has two to five amino acid residues and at least two of the residues are aspartic acid residues; one or more physiologically acceptable minerals comprising at least copper and/or iron; and one or more nutrients and/or drugs sensitive to degradation by the copper and/or iron; wherein the one or more peptides preferably do not contain histidine is preferred.
- a composition comprising an effective amount of one or more peptides or a pharmaceutically acceptable salt thereof, wherein each peptide has two to five amino acid residues and at least two of the residues are aspartic acid residues; one or more minerals; one or more nutrients and/or drugs sensitive to degradation or color change by said one or more physiologically acceptable minerals; wherein the effective amount of peptide is sufficient to decrease the rate of degradation of the one or more nutrients and/or of color change and/or drugs by at least 5% is also preferred.
- An example of a method for decreasing the rate of decomposition of nutrients in vitamin-mineral products and/or drug products during ingestion and/or dissolution testing comprises
- each peptide has two to five amino acid residues and at least two of the residues are aspartic acid residues; wherein the one or more peptides preferably do not contain histidine.
- An example of a cosmetic or hair-care product composition comprises a topical carrier and the an effective amount of one or more peptides or a pharmaceutically acceptable salt thereof, wherein each peptide has two to five amino acid residues and at least two of the residues are aspartic acid residues; wherein the one or more peptides preferably do not contain histidine.
- FIG. 1 shows the amount of ascorbate recovered (expressed as a percentage of the labeled content) from USP type 2 dissolution experiment containing a commercially available multivitamin-mineral supplement (la) in the absence and presence of 0.25 mM Asp- Asp or Asp- Asp- Asp over time.
- FIG. 2 shows the oxygen consumption during dissolution of multivitamin-mineral supplement la over time in the absence and presence of 0.25 mM or Asp- Asp- Asp.
- FIG. 3 shows the amount of thiamine recovered at 45 minutes (expressed as a percentage of the labeled content) from a USP type 2 dissolution experiment containing a commercially available multivitamin-mineral supplement (la) in the absence and presence of 0.25 mM Asp- Asp or Asp- Asp- Asp over time.
- FIG. 4 shows the half-life of 5-methyltetrahydrofolate as a function of Asp-Asp-Asp
- FIG. 5 shows the loss of 5-methyltetrahydrofolate in a homogenous air equilibrated solution of 3 mM ferrous iron in MES buffer pH 6.2 at 37 C in the absence and presence of 3 mM Asp- Asp- Asp tetrasodium salt.
- FIG. 6 shows the loss of ascorbic acid, folic acid, thiamine and vitamin B12 all together in a homogenous air equilibrated solution of 150 micromolar cupric sulfate in MES buffer pH 6.2 at 37 C in the absence and presence of 3 mM Asp- Asp- Asp tetrasodium salt.
- compositions of the present technology are a food, a vitamin and mineral supplement, a topical drug, an oral drug, a cosmetic, or hair care product and one or more multiple aspartate peptide(s), wherein said peptide is present in an amount capable of slowing degradation of said food, a vitamin-mineral supplement, topical drug, oral drug, cosmetic, or hair care product.
- Di-, tri, tetra and penta-peptides are preferred.
- Additional acidic residues in these multiple aspartic acid peptides are such as glutamic acid, sulfonated amino acids, phosphorylated amino acids, and gamma-carboxy-glutamate can also increase effectiveness.
- Examples of multiple aspartate peptides are, but are not limited to, diaspartic acid, and tripeptides, tetrapeptides, and
- pentapeptides that contain at least two residues of aspartic acid. Mixtures of different peptides are also useful such as those having different sequences. It is preferred that at least one of the peptides in such a mixture contain at least two aspartic acid residues. Multiple aspartate peptides can be predominately of one chain length, or mixtures of different lengths.
- One example is a mixture of diaspartic acid, triaspartic acid, tetraaspartic acid, and pentaaspartic acid. For such mixture it is preferred that the most abundant form be triaspartic acid.
- the compositions and methods described herein are suitable for both human and animal use, where the latter includes, among others, cats, dogs, cows, sheep, pigs, and poultry.
- the phrases“diaspartic acid,”“triaspartic acid,”“tetraaspartic acid” and “pentaaspartic acid” or salts thereof refer to peptide sequences of aspartic acid, e.g. Asp- Asp, Asp- Asp- Asp, Asp-Asp-Asp- Asp, Asp-Asp-Asp- Asp- Asp, and calcium Asp-Asp, respectively. They do not refer to separate (non-covalently linked) amino acids.
- calcium diaspartate does not signify a salt of calcium containing two separate (non-covalently bound) aspartic acid molecules (CAS:
- those which are not aspartic acid can be any of the amino acids found in proteins, for example, glutamic acid, (which is especially preferred), glycine, alanine, valine, leucine, isoleucine, serine, cysteine,
- compositions described herein include, but are not limited to, phosphorylated amino acids (e.g., phosphoserine, phosphothreonine, phosphotyrosine, phosphoaspartic acid, phosphoglutamic acid, phosphohistidine, phosphocysteine, etc.), gamma-carboxy-glutamate, pyrrolysine, selenocysteine, hydroxylated amino acids (e.g., asparagine, aspartic acid, proline, lysine, etc.), alkylated amino acids (e.g., methylated forms of histidine, lysine, glutamic acid, etc.), sulfonated amino acid (e.g., serine, threonine, tyrosine, etc.), citrulline, N- and O-glycosylated amino acids.
- triaspartic acid is preferred, although
- tetraaspartic acid is just as effective on a molar basis. Tetraaspartic acid has a higher molecular weight and potentially requires additional synthetic steps than triaspartic acid. Ala- Asp-Asp was found to be about half as effective on a molar basis as triaspartic acid, although its lower molecular weight makes up for some of this difference on a per weight basis.
- peptides containing residues that are fully or partially racemic can be effective, it is preferred that the peptides be substantially chiraly pure at each position in the sequence.
- Asubstantially® it is meant that chiral purity of the residue in each position be greater than 80 %, or more preferably greater than 90 %, and most preferably greater than 95 %.
- the peptides can have some residues which are the substantially pure L-isomer, and contain other residues which are the substantially pure D-isomer.
- Peptides made of some or all residues that are predominately the unnatural D- isomers can also inhibit metal catalyzed oxidation reactions.
- D-amino acids which can be detected in blood and urine.
- D-aspartic acid is biosynthesized in the human brain.
- the rate of proteolysis can be controlled by inclusion of a D-amino acid as part of the multiple aspartate peptide.
- hair itself often contains significant bound metal (such as copper or iron) that affect its properties.
- Uptake of a metal from the intestinal tract can be influenced by the several factors controlled by the peptides to which it is bound. Moreover, clearance of peptides from the digestive tract can occur by several mechanisms. For example, the peptide can be proteolyzed into its amino acid constituents which will have lower affinity for the metal, allowing for its subsequent uptake into the enterocyte. Uptake of transition metals can enhance stability of the other sensitive nutrients still remaining in the intestinal tract. In addition, a considerable portion of the total intestinal uptake of amino acids occurs in the form of di- and tri-peptides, which are substrates for several peptide transporters as well as by a paracellular route.
- the use of a small peptide to quench the redox activity of the transition metals present in a food or supplement has the advantages over other chelating agents in being ultimately digestible and exposing the consumer only to natural products.
- the selection of the amino acids in the peptide which are not aspartic acid can, in part, be tailored to a give an optimal rate of proteolysis in the digestive tract. This, in turn, can modulate the release of the bound transition metals.
- the sequence Asp- Asp- Asp (single letter code: DDD) is found naturally within many larger proteins in microbes and eukaryotes. For example, this is found in within lactalbumin, caspase 3, and coagulation factor VIII.
- the sequence Asp- Asp- Asp- Asp (DDDD) has been found among the peptides contained in hydrolyzed beer yeast Thus, humans have long been exposed to similar peptides resulting from digestion of dietary protein indicating that they are safe for consumption. Large proteins in of themselves are, however, not efficient for use in vitamin preparations even if they both bound metal and hindered its redox reactions due to their much high molecular weights.
- peptide amide linkages are made through the alpha amino and carboxyl groups
- peptides linked via the beta carboxyl group of aspartic acid, the gamma carboxyl group of glutamic acid, and/or the epsilon group of lysine can also be useful for controlling the redox activity of transition metals.
- Glutathione and folate polyglutamic acids illustrate some naturally occurring peptides with gamma-linkages. Peptides containing such linkages are still capable of being cleaved by proteases.
- Examples of a multiple aspartate peptides containing a beta-linkage are a-Asp-p-Asp, a-Asp-a-Asp-P-Asp, a-Asp-P-Asp-a-Asp, and a-Asp-P-Asp-X, where X is another amino acid as described above.
- a hydrophobic residue for example, valine, leucine, isoleucine, methionine, or phenylalanine
- the ratio of metal, metals, and/or other cations such as choline to the multiple aspartate peptide, in vitamin-mineral or other nutritional product, topical or oral drug product, or cosmetic product can be variable. More relevant to effectiveness in preventing product degradation is the total amount of the multiple aspartate peptide or multiple aspartate peptides.
- the preferred range of peptide can be based on the mole amount in the product composition that minimized degradation both on the shelf and during digestion or dissolution testing.
- For food, topical or oral drugs, and cosmetic products minimization degradation during the shelf life is of particular importance.
- Use amounts of, for example, triaspartic acid can be between about 0.01 millimoles to about 3 millimoles per serving size (for example, 0.01 mmole, 0.02 mmole, 0.03 mmole, 0.04 mmole, 0.05 mmole, 0.06 mmole, 0.07 mmole, 0.08 mmole, 0.09 mmole, 0.1 mmole, 0.15 mmole, 0.2 mmole, 0.25 mmole, 0.3 mmole, 0.4 mmole, 0.5 mmole, 0.6 mmole, 0.7 mmole, 0.8 mmole, 0.9 mmole, 1.0 mmole, 1.1 mmole, 1.2 mmole, 1.3 mmole, 1.4 mmole, 1.5 mmol
- the serving size is that quantity of product indicated on the product label that when consumed per occasion delivers the labeled nutrients.
- a serving size for a vitamin mineral product might be one tablet or capsule, but also can be labeled as two or more tablets or capsules.
- the above range refers to the amount of each individual peptide.
- Other multiple aspartate peptides can require different total amount to achieve similar effectiveness (as can be judged, for example, by USP dissolution experiments).
- the mole amount of Ala-Asp- Asp needed is about twice that of Asp- Asp-Asp to provide similar effectiveness. With a lower amount of added transition metal, e.g.
- the total amount of added peptide can be lower to produce a desired level of product stability. It should, thus, be appreciated that an important factor is the total amount of the peptide or peptides in the composition, regardless of which salt or acid forms are added in relation to the amount of transition metals present.
- the amount of a peptide contained in a vitamin-mineral product for the purpose of slowing its degradation can be specified by the total moles of peptide in a serving size. This is more informative than specifying only its ratio to of any of the potentially several metals in the product.
- the optimal amount depends on the particular constituents of the vitamin-mineral or other nutritional product since the presence of high concentrations of some metals can decrease the effectiveness by competition for binding of the peptide or peptides even if not promoting degradation in of themselves.
- the optimal amount can be determined by dissolution or other stability assays for each product formulation.
- the effective amount of a multiple aspartate peptide or peptides in a composition is that that which can slow the rate of degradation by at least than 5 %, preferably at least 10 %.
- the amount of peptide is preferably given as the molar concentration.
- the difference between specifying the mole amount given for a vitamin-mineral supplement composition versus a molar concentration for the food, topical or oral drug, or cosmetic composition is due to the need for slowing the degradation of the former occurring after dissolution into a certain volume of either digestive juices or into a simulating test thereof.
- the degradation (such as oxidation, discoloration, development of rancidity, or by microbial contamination) is primarily desired to be slowed during storage, in which case the volume of the product is approximately known, and a concentration can be specified.
- a hair care product can, in addition, protect the hair from copper, iron, or other metals already bound within the hair.
- this concentration can be between about 0.02 mM and about 6 mM (for example 0.02 mM, 0.03 mM, 0.04 mM, 0.05 mM, 0.06 mM, 0.07 mM, 0.08 mM, 0.09 mM, 0.1 mM, 0.15 mM, 0.2 mM, 0.25 mM, 0.3 mM, 0.4 mM, 0.5 mM, 0.6 mM, 0.7 mM, 0.8 mM, 0.9 mM, 1.0 mM, 1.1 mM, 1.2 mM, 1.3 mM, 1.4 mM, 1.5 mM, 1.6 mM, 1.7 mM, 1.8 mM, 1.9 mM, 2.0 mM, 2.25 mM, 2.5 mM, 2.75 mM, 3.0 mM, 2.25 mM, 3.50 mM, 3.75 mM, 4.0
- the volume used for calculating the added the multiple aspartate containing peptide is the combination of the product and the packing medium.
- the multiple aspartate peptide or peptides can conveniently be added first to the liquid packing medium, or to the combination of the medium with the product.
- a product having a total (product plus medium) volume of 8 fluid ounces (237 mL) would contain between about 0.005 mmoles and 1.4 mmoles of, for example, triaspartic acid to achieve the above
- concentration range A one ounce product would contain between about 0.6 micromoles and 177 micromoles. Due to the large variability of potential product weights for food, topical or oral drug, cosmetic or hair compositions, it is thus clear that a molar concentration is more meaningful than a mole amount (the latter being more appropriate for the above vitamin-mineral compositions. Multiple aspartate peptides other than triaspartic acid can require different molarities to achieve similar effectiveness in slowing degradation. For example, the
- concentration of diaspartic acid needed to achieve an effectives similar to triaspartic acid can be about twice those described above in this paragraph for triaspartic acid.
- concentration of diaspartic acid needed to achieve an effectives similar to triaspartic acid can be about twice those described above in this paragraph for triaspartic acid.
- concentration of diaspartic acid needed to achieve an effectives similar to triaspartic acid can be about twice those described above in this paragraph for triaspartic acid.
- concentration of diaspartic acid needed to achieve an effectives similar to triaspartic acid can be about twice those described above in this paragraph for triaspartic acid.
- concentration of diaspartic acid needed to achieve an effectives similar to triaspartic acid can be about twice those described above in this paragraph for triaspartic acid.
- EDTA ethylenediamine tetraacetic acid
- the improvement in the stability of the components with increasing multiple aspartate peptide was discovered to follow a asymptotic curve.
- the amount of tetrasodium l,l,l-triaspartate in a USP type 2 dissolution experiment required to give half of the maximal stability of the ascorbic acid component of a particular multivitamin-mineral product was about 11.3 mg (0.025 mmoles peptide in a 0.5 L test volume).
- a greater level of stabilization can be achieved with a higher amount of peptide, but at the expense of increased product weight. It can be appreciated that since the total weight/size of a vitamin-mineral tablet or capsule, etc.
- any counter-ion associated with the multiple aspartate peptide or peptides have more nutritional value than sodium (for example, potassium or magnesium), though sodium is effective.
- the free acid can be used preferably if appropriately neutralized during dissolution by the other product components.
- the pH of a vitamin-mineral product containing a multiple aspartate peptide should be above about pH 6 upon dissolution. Since the free acid form of the multiple aspartate peptides can contribute to the overall acidity, this can be converted to a more neutral salt form or forms. Alternatively, the presence of alkaline substances in the vitamin-mineral product, for example calcium carbonate or magnesium oxide, can be used to adjust the pH to be in the optimal range once dissolved.
- the copper present in a vitamin-mineral product can be added as a preformed salt with a multiple aspartate peptide, or formulations where the multiple aspartate peptide is added as a different salt form, or as a combination with other salt forms in addition to that with copper.
- Other salt forms of the multiple aspartate peptides include sodium, potassium, magnesium, and calcium, or any other metal to be added to the vitamin-mineral product.
- the magnesium or calcium salts are particularly useful since these often are present as a considerable percentage of the total weight of the final product. When the multiple aspartate peptide is used in substitution for the carbonate, citrate, fumarate, or other counter-ions often accompanying these metals, the extra weight due the peptide is offset by that which would otherwise be present.
- 1-triaspartate (not counting any water of hydration) would provide 0.125 mmol of l,l,l-triaspartate and 7.5 mg of elemental calcium. Had this amount of calcium instead been included in the form of its citrate salt, this would have added about 31 mg (not counting any water of hydration). In this case, product weight increases only about 21 mg per dose by the substitution of triaspartate for citrate.
- the effectiveness of multiple aspartate peptides is optimal above about pH 6, some dosage formulations can benefit from enteric coatings, or other strategies that as are well known in the industry, that delay dissolution until after any stomach acid has been neutralized by the digestive tract.
- the metals in a vitamin-mineral product can be present either in a salt form well understood to the art of such products, or as metal-peptide complex, or both.
- copper is typically present in products as cupric sulfate, cupric oxide, cupric citrate, cupric acetate, copper sebacate, cupric bis-glycinate and other amino acid chelates, and the like.
- Iron is typically present in products as ferric oxide, ferrous fumerate, ferrous sulfate, ferric phosphate, ferrous bisglycinate chelate, carbonyl iron, ferrous succinate, ferrous aspartate, ferrous gluconate, micronized elemental iron, and as a hydrolyzed protein complex.
- These can be present as such salt(s) or chelates along with multiple aspartate peptide(s) (either as a free acid and/or as the salt of a different metal (such as potassium, sodium, magnesium or calcium, etc.), or as a copper or iron salt of a multiple aspartate peptide, or both.
- Multiple aspartate peptide salts of yet other transition metals are also useful.
- Transition metals essential for mammalian life with multiple valence states where inclusion of a peptide can be advantageous in controlling product degradation include vanadium, chromium, manganese, iron, cobalt, nickel, copper, and molybdenum. These metals are often added, along with other metals, to vitamin-mineral products. Iron and copper can be especially problematic due, in part, to their high amounts in multivitamin-mineral products. Other transition metals can be found in multivitamin products or foods that are not essential for mammalian life, but which can in any case cause degradation of components of the multivitamin product or the food, and which can benefit from inclusion of a multiple aspartate peptide.
- zinc is another essential transition metal that is present in a large amount (U.S. Daily Value 15 mg) in many vitamin-mineral products. Although ionic zinc has only a single valence state (+2), it none the less is known to catalyze, or co-catalyze with other metals, oxidation reactions.
- the salts of several peptides can be hygroscopic to the point of becoming sticky in high humidity environments. It was also discovered that combining such hygroscopic compounds with certain matrices, while not necessarily preventing uptake of water, can none the less produce a novel composition that unexpectedly can be easily handled.
- One such matrix is microcrystalline cellulose which is commonly used as an excipient in vitamin and mineral products.
- a method of combining the peptide salt with the excipient was also developed in which the former is dissolved in a suitable solvent, for example water, the excipient added with stirring, and removing the solvent from the mixture, for example by rotary evaporation under reduced pressure or lyophilization.
- the weight ratio of matrix to the peptide salt can be between about 0.1 to 10, preferably 0.2 to 2.
- the resulting solid can then be crushed to give the appropriate particle size (for example between 100 and 400 mesh) for homogeneous distribution when added to the other vitamin and mineral ingredients.
- Other examples of matrices useful for making more easily handled peptide compositions include powdered cellulose, cellulose, kaolin, talc, silica and silicic acid.
- compositions containing the di, tri, tetra or penta-multiple aspartate containing peptide or peptides can also include nutrients and foods that do not necessarily contain explicitly added transition metals (such as iron or copper), but which contain such metals endogenous to food ingredients. In addition, appropriate foods are also those to which a transition metal has been added.
- the amount of peptide in the composition is that which significantly inhibits degradation (for example, by oxidation, discoloration, or microbial accumulation).
- Examples of foods which can contain the peptide are, but are not limited to, baby foods and infant formula, ready to eat cereals, formulated bars (such as energy bars), pickled cabbage, carbonated soft drinks, white potatoes (for example canned or frozen), clams (for example canned), crabmeat (for example canned), pickled cucumbers, alcoholic beverages, dressings (such as salad dressing), egg products, fermented malt, beverages (examples: any fruit juice, flavored water containing ascorbic acid), legumes (for example, black-eyed peas, canned lima, pinto, kidney, garbanzo, pink or red beans), mayonnaise, mushrooms (for example canned), oleomargarine, pie filling (for example pecan or strawberry), potato salad, sauces, shrimp, spice extractives in soluble carriers, spreads (for example sandwich spread), fish (for example Gefilte fish).
- bars such as energy bars
- pickled cabbage carbonated soft drinks
- white potatoes for example canned or frozen
- clams for example canned
- compositions containing the di, tri, tetra or penta-peptide or peptides containing two or more aspartates can also be antimicrobial formulations wherein the peptide or peptides are a potentiating and/or sensitizing agent for other antimicrobial compounds.
- Such formulations can be used for wounds, suture materials, contact lenses, intraocular lenses and the like.
- These peptide or peptides can be combined with other antimicrobials such as benzalkonium chloride, cetylpyridinum, chloramphenicol, chloroxylenol, chlorohexidine, imipenem, oxytetracydine, penicillin, polymyxin B sulfate, tricolsan among others.
- Such antimicrobial formulations can be effective against Gram-negative, Gram-positive bacteria, amoeba, fungi and yeasts, and can be used to help prevent and/or decrease biofilm development.
- Nutrient product compositions for which multiple aspartate peptides can be effective range from those containing only a single nutrient (for example, a vitamin) and a single transition metal (for example iron or copper) to more complex multi-nutrient and/or multi-metal compositions.
- An example of a product to which multiple aspartate peptide(s) can be incorporated having two active ingredients is a hematinic containing vitamin C and a form of iron such as those listed above.
- Hematinic products often contain additional nutrients such as a folate (e.g., folic acid, 5- methyltetrahydrofolate, 5-formyltetrahydrofolate) and vitamin B12 among others.
- multiple aspartate peptide(s) can be a component of more complex compositions such as multiple vitamin-mineral products containing numerous vitamins and other nutrients (such as amino acids, proteins, nucleic acids, or unsaturated lipids), or micronutrients, (such as carotenoids, e.g. beta-carotene, lycopene, lutein, zeaxanthin, and astaxanthin; polyphenols, e.g.
- multiple aspartate peptide(s) can be a component of a multiple vitamin-mineral composition that in addition include natural products or foods as extracts or powders or oils, or any product sold as a supplement. The form of these
- compositions include, but are not limited to, pills, tablets, capsules, caplets, powders, gels, gummies, chews, effervescents, lozenges, confectionery, etc. While some of these are solid products, others are liquid compositions, examples of which are liquid vitamin products, syrups, mouthwashes, suspensions, complete diets, infant diets, dietary supplements and weight loss products.
- vitamins that can components of the multiple vitamin-mineral products of this invention are vitamin C (ascorbic acid and/or its salts), vitamin A (in its various forms such as retinyl acetate, retinol, retinyl palmitate, retinal, vitamin A precursor carotenes, e.g. beta- carotene), vitamin B7 (e.g., biotin), vitamin D (in its various forms such as cholecalciferol, ergocalciferol), 25-hydroxycholecalciferol, 25-hydroxyergocalciferol), vitamin B12 (in its various forms such as cyanocobalamin, methylcobalamin, adenosylcobalamin,
- vitamin B5 in its various forms such as pantothenic acid, calcium
- vitamin E in its various forms such as alpha, beta, gamma or delta-tocopherols or mixtures thereof, and/or alpha, beta, gamma or delta- tocotrienols, or mixtures thereof, as well as esters of these such as tocopheryl acetate
- vitamin B9 folate in its various forms such as folic acid, 5-methyl-tetrahydrofolic acid, 5-formyl- tetrahydrofolic acid, 10-formyl -tetrahydrofolic acid, 5,l0-methylene-tetrahydrofolic acid, 5,10- methenyl-tetrahydrofolic acid, 5-formimino-tetrahydrofolic acid, tetrahydrofolic acid
- vitamin B3 in its various forms such as niacinamide, nicotinic acid, nicotinamide riboside as well as biomolecules incorporating these such
- vitamin B6 in its various forms such as pyridoxine, pyridoxine-5 '-phosphate, pyridoxal-5 '-phosphate, and pyridoxamine
- riboflavin as well as its enzymatically active forms flavin mononucleotide and flavin adenine dinucleotide
- vitamin B1 thiamine and such forms as its mononitrate and hydrochloride salt, as well as its various phosphate derivatives.
- vitamin C, biotin, vitamin A, folate, vitamin B12, vitamin D, vitamin E, and vitamin K can be especially susceptible to oxidation, particularly if metal catalyzed, for example by iron or copper.
- Vitamin-mineral compositions and multivitamin-mineral compositions can in addition to essential and nonessential nutrients also contain excipients that provide a number of useful attributes such as, antiadherents, binders, coatings, colors, disintegrants, flavors, glidants, lubricants, preservatives, sorbents, sweeteners, vehicles.
- useful attributes such as, antiadherents, binders, coatings, colors, disintegrants, flavors, glidants, lubricants, preservatives, sorbents, sweeteners, vehicles.
- examples of these include calcium carbonate, magnesium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, microcrystalline cellulose, powdered cellulose, dextrates, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, or mixtures thereof, agar-agar, alginic acid,
- clays such as kaolin and talc
- other algins other celluloses, gums, or mixtures thereof
- lactose sugar, maltitol, gelatin, polyethylene glycol, methyl cellulose, polyvinylpyrrolidone, hydroxypropyl methylcellulose, waxes, shellac, silica
- the present invention also includes a method for stabilizing a food, vitamin, nutrient, or hair from metal catalyzed degradation.
- the methods involves incorporating an effective amount of multiple aspartate containing di,- tri-, tetra- or penta-peptide or a combination of these into a food, vitamin, or hair-care product.
- Examples of foods to which the peptides can be added are, but are not limited to, baby foods and infant formula, ready to eat cereals, formulated bars (such as energy bars), pickled cabbage, carbonated soft drinks, white potatoes (for example canned or frozen), clams (for example canned), crabmeat (for example canned), pickled cucumbers, distilled alcoholic beverages, dressings (such as salad dressing), egg products, fermented malt, beverages (examples: any fruit juice, flavored water containing ascorbic acid), legumes (for example, black-eyed peas, canned lima, pinto, kidney, garbanzo, pink or red beans), mayonnaise, mushrooms (for example canned), oleomargarine, pie filling (for example pecan or strawberry), potato salad, sauces, shrimp, spice extractives in soluble carriers, spreads (for example sandwich spread), fish (for example Gefilte fish).
- bars such as energy bars
- pickled cabbage carbonated soft drinks
- white potatoes for example canned or frozen
- clams for
- the volume used for calculating the added the multiple aspartate containing peptide is the combination of the product and the packing medium.
- the multiple aspartate peptide or peptides can conveniently be added first to the liquid packing medium, or to the combination of the medium with the product.
- the method of incorporating multiple aspartate peptide(s) can also be used for any combination of individual foods, such as those that are processed or cooked or baked, as well as those that are not heated.
- the nutrient can be a macronutrient, such as a protein, carbohydrate, or fat
- a micronutrient such as carotenoids, e.g. beta-carotene, lycopene, lutein, zeaxanthin, and astaxanthin; polyphenols, e.g. anthocyanidins, catechins, flavonoids, tannins, and procyanidins; and cofactors, e.g., coenzyme Q and glutathione) or essential such fatty acids, essential amino acids, or vitamins).
- carotenoids e.g. beta-carotene, lycopene, lutein, zeaxanthin, and astaxanthin
- polyphenols e.g. anthocyanidins, catechins, flavonoids, tannins, and procyanidins
- cofactors e.g., coenzyme Q and glutathione
- the effective amount of said peptide is that which is sufficient to slow the rate of degradation of at least one vitamin or nutrient component (for example ascorbic acid) or slows the rate of change in color or of microbial contamination by at least 5 %, preferably at least 10 %.
- vitamins or nutrient component for example ascorbic acid
- Examples of methods of this invention are those where the multiple aspartate peptide is of the type described above, e.g.
- concentration of Asp- Asp- Asp to be incorporated to achieve this level of decreased rate ranges between about 0.02 mM and about 6 mM.
- Other multiple aspartate peptide(s) can use more or less than this range depending on their effectiveness relative to Asp-Asp-Asp.
- the rate of degradation for vitamin formulations can be determined in vitro, for example by dissolution methods set forth in the US Pharmacopeia (USP), or by in vivo pharmacokinetic measurements. In the former case, the rate of loss of the vitamin or nutrient itself, and/or the appearance of degradation products can be measured and compared to an identical experiment lacking the peptide.
- USP methodology contains numerous procedures for analysis of content or dissolution rates, etc. that are tailored to the physical form of each product. Among these, for example, Type 1 employs a rotating basket, Type 2 a paddle, Type 3 a reciprocating basket, and Type 4 a flow through cell. In many tests for specific products only a single sample is measured at a specific time.
- samples are analyzed at various times typically over the course of about 120 minutes which encompasses the time of peak absorption of many micronutrients from the digestive tract.
- Various media such as water, phosphate buffer, simulated gastric fluid, dilute hydrochloric acid, etc. can be used for these test.
- Some USP tests call for dearation of the medium, but in the context of this invention the medium is best equilibrated to atmospheric oxygen or some other defined mixture of oxygen in another inert gas such as nitrogen. This permits the measurement of the rate of degradation of the components of a product (such as a multiple vitamin - mineral capsule) in a way simulating the influence of consumption by drink a liquid, such as water.
- the rate of degradation of a nutrient can be determined by comparing the amount observed in an early sample taken from the measuring apparatus and comparing this to that observed in a later sample. It can also be determined by comparing the amount observed at a given time after mixing with the test medium in comparison to the amount that is measured to be in the product before dissolution. In the latter case, the product is dissolved in such a way that avoids exposure to oxygen and/or incorporates agents that inhibit product oxidation.
- the initial content of ascorbic acid in a multivitamin-mineral product can be measured by mixing crushed product in thoroughly deaerated 5 mM EDTA under inert gas, and filtering anaerobically.
- the rate of degradation can be calculated by comparing the measured content of a nutrient in samples at a various times with either the initial content as measured above, or the highest value within the run, or with the labeled content of the nutrient. The same calculation is performed the presence and absence of the peptide, and the ratio of the two measurements is examined for each of the sampling times. For the purpose of determining the effective amount, comparison of the value for the sample time giving the greatest difference between the ratio in the presence vs absence of peptide is preferred.
- the appearance of the nutrient in the blood or urine, and/or the appearance of degradation products in blood or urine can be measured.
- some nutrients such as ascorbic acid
- in vivo pharmacokinetics are difficult to observe at low dose, and in such cases the use of isotope labeled nutrient and/or measurement of degradation products can be advantageous, as is well known in the art of pharmacokinetics.
- the degradation can be catalyzed by metals that are added to a food or vitamin, or those that are intrinsic to a food.
- the rate of degradation of foods or nutrients that are not in the form of tablets or capsules or other such concentrated forms can be examined by the change in individual components, in color, or by microbial contamination over the intended shelf life by analytical methods well known to the art of food and nutrient technology.
- the rate of color change can be measured subjectively by matching colors to a standardize chart, or preferably using a colorimeter, spectrocolorimeter, or spectrophotometer as a function of time.
- the rate of degradation due to increased rancidity can be examined by several tests including the Peroxide Value (PV) which measure the amount of lipid peroxides; the p-Anisidine (p-AV) and Kreis tests which measures the aldehydes/ketones present in lipids; the ThioBarbituric Acid Reactivity (TBAR) test which also measures aldehyde content (especially malondialdehye); and the Oxidative Stability Index (OSI) test which is examines stability to air oxidation under accelerated conditions, frequently using the Rancimat method. These methods can be used in the presences and absence of added multiple aspartate peptide(s) to determine the decrease in rate of degradation.
- PV Peroxide Value
- p-AV p-Anisidine
- TBAR Thi
- aspartate peptides and their salts can also be effective for slowing degradation of cosmetic compositions, for example bath preparations, bath soaps and detergents, fragrance preparations, skin cleansing preparations, moisturizing preparations, deodorants, foundations, aftershave lotion, shaving cream, baby shampoos, bubble baths, body and hand, neck and face preparations, creams, lotions, shampoos, makeup products, lipsticks, eye and facial makeup.
- Hair has been shown to take up copper and iron from a number of sources, including tap water. This leads to increased oxidative degradation of the hair protein, especially in the presence of UV such as in sunlight.
- aspartate peptides and their salts can be especially useful in cosmetic preparation used on hair, for example hair shampoos, conditioners, dyes, permanent waves, and colors, etc. They can also be effective in topical or oral drugs such as sunscreens, for products regulated both as a cosmetic and drug such as moisturizing sunscreens, and for other dermatologic drugs.
- sunscreens for products regulated both as a cosmetic and drug such as moisturizing sunscreens, and for other dermatologic drugs.
- These peptides can stabilize and enhance antioxidants such as ascorbate, tocopherol, and retinol frequently used in and topical or oral drug compositions and cosmetic products.
- the degradation of hair and its improvement as a result of using hair products containing multiple aspartate peptide(s) can be assessed by a number of measurements known to the art, for example shine, breakage, and combing force, as well as by analytical techniques such as mass spectroscopy. It is preferred that the decrease the degradation of hair as measured by these or other methods be greater than 5 % in comparison to a similar composition lacking multiple aspartate peptide(s).
- the multiple aspartate peptides of this invention can be added in powdered solid form to the food, vitamin-mineral supplement, topical or oral drug, or cosmetic.
- this powder can be mixed and made sufficiently homogeneous with the other solid components by the methods well known in the art of pharmaceutical and supplement manufacturing.
- the added peptide can be dissolved in this water are made homogeneous by mixing.
- the peptide can be first dissolved in a suitable solvent, for example water or glycerol.
- the solubility of the peptide, for example a multiple aspartate peptide is increased as a salt form, for example as a sodium or potassium salt.
- transition metals on the degradation (such as by oxidation) of nutrients can, in addition to the inclusion of a multiple aspartate peptide, be further hindered by the use of slowly dissolving form of the metal.
- the metal can be in the form of a salt with intrinsically low dissolution rate, or a form that is incorporated into a matrix, for example by microencapsulation, as is known to the art of bioavailability manipulation. It should be understood that in establishing the effective rate of dissolution of a slowly dissolving form of the metal according to USP methodology it is preferable to measure this in the presence of the other ingredients in a product, rather than simply by itself in water or buffer.
- dissolution can be influenced by the other product ingredients, in many cases producing faster rates, for example of copper salts, than in water only.
- a slowly dissolving form of a transition metal for example copper, can further hinder the destruction of nutrients in addition to the inclusion of a multiple aspirate peptide.
- Solvent was removed by rotary evaporation at reduced pressure, 60 ml of ethyl acetate added, the resulting solution washed with 3 x 75 ml of water. Solvent was removed by rotary evaporation at reduced pressure and the product dried under high vacuum over P 2 0 5 to give 11.6 g of BOC-Asp-Asp-Bn 3 as a light tan powder.
- Asp-Asp-Bn 3 All of the above BOC-Asp-Asp-Bn 3 was dissolved in 20 ml of anhydrous dimethoxyethane under a blanket of inert gas and placed on ice. To this was quickly added 25 ml of HC1 in anhydrous dimethoxyethane (saturated by 45 minutes of bubbling HC1 on ice) with vigorous stirring. After 45 minutes the reaction was removed from the ice and allowed to warm to room temperature. HPLC as above indicated complete disappearance of starting material by 115 min. Solvent was removed by rotary evaporation at reduced pressure with two further additions of 25 ml each of fresh DME to facilitate removal of HC1, and the solid kept under high vacuum over NaOH pellets to give a thick orange oil that solidifies on storage.
- Deprotection of BOC-Asp-Asp-Asp-Bi can be performed in either order, but hydrogenolysis of the benzyl groups first has the advantage of requiring less catalyst due to the presence of the protected amino group.
- Asp-Asp-Asp-Bn 4 HC1 All of the above BOC-Asp-Asp-Asp-Bn 4 was dissolved in 24 ml anhydrous DME and cooled in an ice bath, and 26 ml of HC1 saturated in anhydrous
- dimethoxyethane (at 0°C) added with stirring. At 50 min the mixture was allowed to warm to room temperature, and after 90 min solvent was removed by rotary evaporation at reduced pressure. To remove residual HC1, 30 ml of DME was added and removed by rotary
- Asp-Asp-Asp All of the above Asp-Asp- Asp-Br HC1 was dissolved in 220 ml EtOH plus 6 ml DME, 6 g 10 % Pd on charcoal was added, and the reaction bubbled at atmospheric pressure and ambient temperature with vigorous stirring. The disappearance of starting material, less benzylated intermediates and appearance of toluene was monitored by the above HPLC system using ACN/0.l% TFA (53:47). By 90 min all of the peaks absorbing at 255 nm (aside from toluene) were no longer detected, and the reaction mixture was centrifuged for 15 min at 500 x g.
- BOC-Asp-Asp-Asp Crystallized BOC-Asp-Asp-Bn 3 (2.7 g) was fully dissolved in 30 ml anhydrous ethanol, 0.27 g of 10% Pd on charcoal was added, and hydrogen bubbled with stirring at ambient temperature and pressure. By 35 min all the starting material and intermediate levels of benzylation were consumed a judged by the above HPLC system using ACN/0.l% TFA (53:47), the reaction filtered through a 0.22 micron TFE filter, and washed with an additional 10 ml EtOH. Rotary evaporation at reduced pressure, and exposure to high vacuum over P 2 0 5 gave 1.8 g of BOC- Asp- Asp- Asp as a colorless hygroscopic glass.
- Asp-Asp-Asp All of the above BOC-Asp-Asp-Asp was dissolved in 50 ml anhydrous DME and placed in an ice bath. To this was added with stirring 50 ml of DME freshly saturated on ice with HC1 gas. After 30 min all of the BOC protecting group had been removed as measured by the above HPLC system using ACN/0.l% TFA (1:8), and the mixture rotary evaporated at reduced pressure to a about 10 ml, whereupon the product precipitated. Unexpectedly, further product can be driven out of solution by brief warming (for example, to about 50°C), and obtained by rapid filtration while still warm.
- the HC1 salt of Asp- Asp-Asp is obtained as a hygroscopic powder.
- This material is typically greater than 90 % pure based on 230 nm absorbance area in the above HPLC system using 100 % of 0.1 mM TFA as mobile phase. It can be further purified by preparative HPLC on Kromasil Cl 8 using 0.1 mM TFA to give the TFA salt after evaporation.
- Triaspartic acid can be crystallized from water after adjustment to about pH 3.
- 1,1,1-His-Asp-Asp and 1,1,1-Ala-Asp-Asp These compounds were synthesized by methods similar to the above, but using N”,N im -Bis-Boc-L-histidine N-hydroxysuccinimide ester and Boc-L-alanine N-hydroxysuccinimide ester, respectively, for addition of the third residue to Asp- Asp-Bn 3 .
- catalytic hydrogenolysis of the benzyl protecting groups was performed before the final removal of BOC group.
- Product la was found to contain on average 120 % of the labeled amount of 60 mg per dose (i.e., 72 mg), all of which was irreversibly destroyed by 80 minutes in the standard dissolution test (FIG. 1). Importantly, dehydroscorbate was not detected at any time. This loss of ascorbic acid was accompanied by a rapid decrease in the oxygen concentration of the aqueous dissolution medium which reached nearly 0 percent by about 10 minutes. With continued stirring by the USP paddle, 0 2 was slowly reintroduced after 45 minutes but did not reestablish air saturation even by 115 minutes (FIG. 2).
- the oxygen consumption due to dissolution of this tablet containing CuO was also slower in reaching a minimum of about 10 % after about 70 minutes.
- the profile of ascorbate and oxygen decreases due to product #lb were very similar to those of Product #la if 2 mg of copper as CuS0 4 was added to the 500 ml of water prior to the tablet.
- the rate produced by Product #lb in the presence of 1 mg of copper (as CuS0 4 ) added to the dissolution medium was slower than with 2 mg, as was the maximum rate of oxygen consumption.
- the total content of the thiamin (vitamin Bl) in the above product #la was determined using crushed tablets and was found to average about 125% higher than the 2.4 mg labeled amount. Examining the filterable thiamin during USP type 2 experiments as above showed that the amount in solution at 10 minutes was only 67 % of the total actual content on average (84% of the labeled content). This did not change significantly after 45 minutes of dissolution (FIG. 3).
- the appearance of folic acid in Product #la during USP type 2 dissolution experiments was influenced by two factors. First, the great majority of the total folic acid content remained sequestered in non-filterable particulate matter. The actual final content of folic acid was determined after 150 minutes by adding sodium hydroxide to a final concentration of 25 mM, disodium EDTA to a final concentration of 5 mM, and sonicating the mixture for 5 minutes prior to 0.22 micron filtration. This indicated that the total amount of intact folic acid at 150 min was typically about 160 % of the 0.40 mg labeled value.
- the time at which folic acid starts to appear more rapidly in solution approximately corresponds to when the dissolved oxygen begins to increase again as a result of stirring by the USP paddle. If at any time during a dissolution experiment the solids are harvested by centrifugation and treated by sonication with 25 mM NaOH/5 mM Na 2 EDTA, folic acid can be found in the filtrate in an amount similar to that detected at the end of a typical run at 115 min. This shows that in Product #la folic acid is sequestered in the solids and only very slowly leaches into solution. The course of folic acid release into solution is very different with Product #lb (which incorporates insoluble cupric oxide instead of soluble cupric sulfate).
- the final total content of folic acid is also about 160 % of the labeled value as with #la.
- the final total content of folic acid is also about 160 % of the labeled value as with #la.
- the final total content of folic acid is also about 160 % of the labeled value as with #la.
- even after 10 minutes of dissolution around 55 % of the labeled value typically appears in a filtered sample, which increases to about 65 % after 45 minutes of dissolution and on average does not further increase even in a 115 minute sample.
- Product #2 A multivitamin-mineral supplement tablet from a second manufacturer also designated for use by women was labeled to contain 2 mg of copper (as CuS0 4 ) and 18 mg of iron as ferrous fumarate was also examined.
- the total vitamin C content as determined above was on average 225 mg, i.e. 125% of the labeled amount (180 mg, 300% of the Daily Value).
- little ascorbate was present in the 10 minute sample, but increased to a maximum in the 45 minute sample and then slowly declined. A. This maximum amount was on average about 79 % of the labeled amount, or 63 % of the actual initial content. This represents a loss of about 83 mg of ascorbic acid on average.
- the concentration of dissolved oxygen falls to nearly zero after only a few minutes, and (in contrast to Product #1) remained very low despite continued stirring with the USP paddle.
- Product #3 A tablet from yet another manufacturer labeled to contain 150 mg (250% of the Daily Value) of vitamin C and 2 mg of copper (as amino acid complex), but no explicit iron, did not disintegrate as quickly as those from manufacturers 1 or 2. Probably as a result, many of the nutrients did not quickly appear in solution. In particular, ascorbic acid did not reach a maximum concentration until between 45 and 80 minutes, where it was only 38% of the labeled amount. The total content of ascorbic acid in Product #3 was not determined, thus the missing 62% represents the destruction of a minimum of 93 mg of vitamin C.
- Product #4 A tablet from a fourth manufacturer which contained neither any copper nor significant iron did not release much of its nutrient content by 10 minutes of dissolution: for example of the labeled amount of ascorbic acid (110 mg) only 7% was found in a sample at this time. However, the 45 minute sample showed 151% of the labeled amount which was nearly the same as measured at 80 minutes (157%). Over the course of the dissolution run dissolved oxygen slowly decreased only to about 68% of its initial value. This product which contains no transition metals did not appear to suffer from meaningful destruction of its vitamin C or its other nutrients.
- the vitamin C in a multivitamin-mineral supplement can be rapidly degraded especially in the presence of copper and/or iron.
- the amount of the loss may be limited by the amount of dissolved oxygen present in the dissolution vessel, or in the liquid used to consume the supplement product. With water equilibrated to air at 37 C this amounts to around 90 mg (0.51 mmole).
- the ascorbic acid in products actually containing less than this can be completely and irreversibly destroyed, for example 100% of the U.S. Daily Value is 60 mg.
- For products containing substantially greater than 90 mg of vitamin C some can remain after the oxygen is consumed, although leaving behind considerable ascorbate degradation products.
- other components in the vitamin-mineral product are also decomposed.
- Example 1 Inclusion of small peptides containing two of more aspartic acid residues was unexpectedly found to greatly increase the amount of ascorbic acid in samples taken from typical USP type 2 dissolution experiments with multivitamin/mineral supplements.
- the molar ratio of copper (2 mg, 0.0315 mmol) to triaspartic acid peptide is about 1 :4, and the molar ratio of copper to all aspartic acid residues is about 1 :12.
- the amount of thiamine present at 45 minutes increased to an average of 83 % of the actual content of these tablets (104 % of labeled content) in comparison to 67 % (84 % of labeled content) without Asp- Asp- Asp (FIG. 3).
- Increasing amount of peptide can further benefit the maintenance of ascorbic acid and thiamine.
- Example 2 USP type 2 dissolution experiments were performed on Product #lb formulated with CuO, but with either 1 or 2 mg of copper added to the water medium as CuS0 4 and also tetra- sodium 1,1, 1-triaspartate in concentrations varied from 0.05 to 0.5 mM.
- the rate of loss of ascorbic acid in the presence of 2 mg of added copper and 0.25 mM Asp- Asp- Asp was similar to that found with Product #la (which contains 2 mg of Cu as CuS0 4 endogenously) in the presence of 0.25 mM Asp-Asp- Asp. This shows that the effect of the Asp-Asp-Asp peptide is the same whether the soluble copper is in the dissolution medium or from the tablet itself.
- the concentration of Asp- Asp- Asp required for 50 % of maximal effectiveness in preventing ascorbate loss was calculated by fitting to a hyperbolic response curve to be about 0.05 mM.
- the maximal benefit of Asp- Asp-Asp in this experiment requires a higher mole amount than the mole amount of the copper.
- the results with 1 mg of copper added to the water medium as CuS0 4 were consistent with this finding in that a somewhat lower concentration of Asp- Asp- Asp was required for half maximal effect in preventing loss of ascorbate.
- Example 3 A USP type 2 dissolution experiment was performed on Product #lb formulated with CuO, but with a Cu ⁇ l/ 3 ) Ca 2 -l,l,l-triaspartate/crystalline cellulose powder added to the water medium simultaneously with the tablet.
- the weight ratio of the Cu ⁇ i /3) Ca2-triaspartate to cellulose was 1:1, and the final concentration of copper in the medium was equivalent to 1 mg and the concentration of Asp- Asp- Asp was 0.093 mM.
- the profile of ascorbate loss, and appearance of thiamine and folic acid was not significantly different from similar runs as described in Example 2 with 1 mg of copper and 0.1 mM Asp- Asp- Asp not added as a preformed calcium-copper salt.
- the effectiveness of Asp-Asp-Asp is not influenced by its being provided as in a cellulose matrix.
- Example 4 Inclusion of tetra-sodium 1,1,1-triaspartate (1 mM) in the dissolution of product #2 increased the average recovery of thiamine at 45 minutes by 20 % over that obtained with no added peptide.
- the ascorbate appeared in solution more quickly in the presence of Asp-Asp- Asp, and the average recovery of ascorbic acid from product #2 (which is labeled to contain 300 % DV) at 45 minutes in these experiments was increased by 16 % in comparison to those performed without a peptide.
- the profile of p-aminobenzoyl-glutamate formation was suppressed in comparison to without any peptide, and similar to 0.05 mM Asp-Asp-Asp.
- the profile of thiamine appearance in solution was not significantly different than without peptide.
- the rate of oxygen consumption was less than without a peptide.
- Asp 2 is effective in making some vitamins more available in solution and protecting them from degradation, it is less effective per weight of peptide than Asp-Asp-Asp, even though the latter has a 46 % higher molecular weight.
- Simple aspartic acid i.e ., not formed into a peptide
- Example 7 The decay of 25 mM calcium 5-methyltetrahydrofolate (5-MTHF) in 10 mM HEPES pH 7.2 buffer in the presence of peptide and 150 mM cupric sulfate (added last) was measured.
- 5-MTHF calcium 5-methyltetrahydrofolate
- cupric sulfate in concentrations of above 40 mM resulted in complete loss of 5-MTHF within the first two minutes of incubation.
- Including either tetra- sodium l,l,l-triaspartate or penta-sodium l,l,l,l-tetraaspartate increased the half-life of the 5-MTHF in a concentration dependent manner (FIG. 4); with 2 mM giving 198 and 178 minutes respectively.
- Asp-Asp-Asp and Asp 4 are similarly effective at a given molarity, the former due to its lower molecular weight has the advantage in terms of weight of peptide per volume.
- Tri-sodium 1,1-diaspartate at 2 mM gave a concentration dependent 5-MTHF half-life of 72 minutes at 2 mM.
- At a concentration of 0.5 mM Asp- Asp- Asp gave a half-life longer than Asp 2 .
- the stability of 5-MTHF improves somewhat with even higher concentrations of peptide; for example with 3 mM and 4 mM Asp 2 its half-life increases to 87 and 100 minutes, respectively.
- diaspartic acid is not quite as effective under these conditions as Asp- Asp-Asp , even on a per weight basis.
- the dipeptides 1,1-aspartyl-glutamic acid, 1-aspartyl-glycine, and 1,1-glutamyl-aspartic acid gave a half-lives that were between 50 to 75 percent of that of Asp 2 (each determined at 0.5 mM as neutral sodium salts, and 25°C).
- the decomposition of 5-MTHF is slower in acidic solutions than at neutral pH, and this was found even in the presence of cupric ions.
- cupric ions For example, at 37 C in 1 mM HC1 (as can be found in the stomach) and in the presence of 150 mM cupric sulfate the time to half decomposition of 5-MTHF was observed to be around 20 minutes (this decay curve was not well described by a lst-order decay). With 3 mM 1,1,1-triaspartic free acid also present the time to half
- Example 8 The decay of 25 mM calcium 5-methyltetrahydrofolate (5-MTHF) in 40 mM MES pH 6.2 buffer in 3 mM ferrous chloride (freshly prepared and added last) was measured. In the absence of a peptide a half-life of 5-MTHF decay of 25 minutes was found. In the presence of presence of 3 mM tetra-sodium 1,1,1-triaspartate no significant loss of 5-MTHF was observed for about 50 minutes, and then deceased by about 17% per hour (FIG. 5).
- Example 9 The effect of cupric sulfate (150 mM) on the combination of folic acid (10 mM) and sodium ascorbate (5 mM) was examined in the following various buffers. Reactions were continuously but slow sparged with air so that oxygen would not become limiting.
- Example 10 The effect of cupric sulfate (150 mM) on the combination of vitamin Bl 2 (10 mM cyanocobalamin), thiamine (1.5 mg/ml as HC1 salt), folic acid (10 mM) and sodium ascorbate (5 mM) was examined in 10 mM MES pH 6.2 slowly sparged with air (FIG. 6). Vitamin B 12 rapidly decreased within the first 26 minutes by about 43% in the absence of an aspartate peptide, but remained constants thereafter presumably due to concomitant depletion of ascorbate. In the presence of 3 mM 1,1,1-triaspartate (as the tetra-sodium salt) the loss of Vitamin B12 was limited to about 20% even after 2 hours.
- Example 11 The effect of 1,1, 1- Ala- Asp- Asp on the decay of sodium ascorbate in 10 mM HEPES pH 7.2 at 37 was compared with 1,1,1-triaspartate in the presence of 63 mM cupric sulfate (equivalent to 2 mg of elemental copper per 500 mL). At a peptide concentration of 0.25 mM Ala-Asp-Asp the lst-order rate of ascorbate loss was almost twice as fast as Asp- Asp- Asp. This difference is somewhat offset by the -12% lower molecular weight of the former.
- Example B Tetra-sodium-l,l,l-triaspartate on microcrystalline cellulose: All of the tetra-sodium- l,l,l-triaspartate from Example A was dissolved in 5 mL of water, 135 mg of microcrystalline cellulose added, and mixed. This was rotary evaporated under reduced pressure at 38°C to a white solid that was placed under high vacuum over P2O5 for 24 hours. The resulting material was crushed to pass through a 200 mesh sieve. On exposure to the atmosphere this gained 11 % in weight as water, but none the less remained free flowing.
- Example C Tetra-potassium-1, 1,1-triaspartate: 1,1,1-Triaspartic free acid (117 mg of 1.5 hydrate, 0.30 mmoles) was dissolved in 5.0 ml of water at ambient temperature, 4 ml of 3 M potassium hydroxide (1.2 mmoles) was added, and the mixture stirred until completely in solution of pH 6 to 7.
- Example D Calcium l 5 -1, 1,1-triaspartate: 1,1,1-Triaspartic free acid (117 mg of 1.5 hydrate, 0.30 mmoles) was dissolved in 5.0 ml of water at ambient temperature, 33 mg (-0.45 mmoles) of calcium hydroxide was added, and the mixture sonicated until completely in solution of pH 6 to 7. This was rotary evaporated under reduced pressure at 38°C to give a clear solid that was placed under high vacuum over P 2 0 5 for 24 hours resulting in free flowing flakes. On leaving open to the atmosphere at ambient temperature this regained -10% weight over the next several days due to uptake of water.
- 0.10 mmoles, 0.125 mmoles, 0.25 mmoles, or 0.50 mmoles of 1,1,1-triaspartate by addition of this material would also add about 3.0 mg. 6 mg, 7.5 mg, 15 mg, and 30 mg to the calcium content from other ingredients, respectively.
- Example E Magnesium 1. 5 - 1 , 1 , 1-tri aspartate : This was produced in the same manner as the above calcium salt, but using magnesium hydroxide instead of calcium hydroxide. Nutrient
- preparations containing, for example, 0.05 mmoles, 0.10 mmoles, 0.125 mmoles, 0.25 mmoles or 0.50 mmoles of l,l,l-triaspartate by addition of this material would also add about 1.8 mg. 3.6 mg, 4.5 mg, 9.1 mg, and 18.2 mg to the magnesium content from other ingredients, respectively.
- Cuprici /4 -Mgi .4 -l,l,l-triaspartate Cupric sulfate-5H 2 0 (34 mg, 0.136 mmoles) was dissolved in 0.4 ml water and 1M sodium carbonate added with rapid stirring to give between about pH 8.5 to 9.5, the mixture centrifuged, and the supemate decanted and discarded. The precipitate was resuspended in 0.5 ml ice-cold water, recentrifuged, and the second supemate discarded.
- Nutrient preparations containing, for example, 0.5 mg, 1 mg, or 2 mg of copper per dose or serving of this material would also add about 1.1 mg, 2.1 mg, and 4.3 mg to the magnesium content due to other ingredients, respectively, and would also add about 0.031 mmoles, 0.063 mmoles, and 0.126 mmoles of 1,1, 1-triaspartate, respectively.
- the triaspartate content per dose or serving can be further increased without changing the copper content by incorporation of triaspartic acid or other non-copper containing salts of triaspartic acid, for example magnesium triaspartate, calcium triaspartate and/or ferrous triaspartate.
- Example G Cupric i /4 -Mg l 4 -l,l,l-triaspartate on microcrystalline cellulose: Cuprici /4 -Mgi. 4 -l,l,l- triaspartate from Example F was put into 2 ml of water with sonication to give a dark blue solution, and an equal weight of USP grade microcrystalline cellulose added. After rotary evaporation to near dryness under reduced pressure at 37C and exposure to high vacuum over P 2 0 5 gave a light blue free flowing powder. This material can be added to nutrient preparation as in Example F, but using twice the weight to give the same amount of copper, magnesium, and triaspartate.
- Example H Cuprici /4 -Cai .4 -l,l,l-tri aspartate: This was made in manner similar to Example F, but using Ca(OH) 2 instead of Mg(OH) 2 .
- Example I Cupric-Ca-l,l, 1-triaspartate on microcrystaUine cellulose: This was made in manner similar to Example G, but using Cupric-Ca-l,l,l-triaspartate instead of Cupric-Mg-l,l,l- triaspartate.
- Cupric 2 2 -l,l,l-triaspartate Cupric sulfate-5H 2 0 (0.15 g, 0.60 mmoles) was dissolved in 1.0 ml water and 1M sodium carbonate added to give pH 9.1, the mixture centrifuged, and the supemate decanted and discarded. The precipitate was resuspended in 0.5 ml ice-cold water, centrifuged again, and the second supemate discarded.
- the triaspartate content per dose or serving can be further increased without changing the copper content by incorporation of triaspartic acid or other non-copper containing salts of triaspartic acid, for example magnesium triaspartate, calcium triaspartate and/or ferrous triaspartate.
- triaspartic acid or other non-copper containing salts of triaspartic acid for example magnesium triaspartate, calcium triaspartate and/or ferrous triaspartate.
- Example K Cupricu-l,l,l-triaspartate. All of the cupric 2 2 -l,l, 1-triaspartate from Example I was put back into solution and another 0.27 mmoles of 1,1,1-triaspartic free acid added, vortexed to a clear blue solution, rotary evaporated to near dryness under reduced pressure at 38C, and put under high vacuum over P 2 0 5 to give blue-green flakes that were free flowing and initially not sticky. Let open to the atmosphere ( ⁇ 50 % relative humidity) this gained 6 % in weight over 3 days and became slightly sticky. On exposure to 70 to 80 % RH for another 24 hours weight gain increased to a total 10 % and the material was wet and sticky.
- Example L Cupricu-l,l,l-triaspartate on microcrystalline cellulose. All of the cupric i .i -1,1,1- triaspartate from example F was to put into solution by addition of 1.0 ml of water. USP grade microcrystalline cellulose was added in an amount equal to half the initial dry weight of the cupri d i -U l-triaspartate, sonicated briefly to distribute, rotary evaporated to near dryness under reduced pressure, and put under high vacuum over P 2 0 5 to give blue flakes. This material on exposure to 70 % RH for a day and then 90 % RH for an additional day gained about 10 % in weight, but did not become sticky.
- Nutrient preparations containing, for example, 0.5 mg, 1 mg, or 2 mg of copper per dose or serving of this material would also add about 0.0072 mmoles, 0.014 mmoles, and 0.029 mmoles of 1,1,1-triaspartate, respectively.
- the triaspartate content per dose or serving can be further increased without changing the copper content by incorporation of triaspartic acid or other non-copper containing salts of triaspartic acid, for example magnesium triaspartate, calcium triaspartate and/or ferrous triaspartate.
- Example M Cupric 3 l -l,l, 1-triaspartate: Cupric sulfate-5H 2 0 (0.137g, 0.55 mmoles) was dissolved in 1.0 ml water and 1M sodium carbonate added to give pH 9.1, the mixture centrifuged, and the supemate decanted and discarded. The precipitate was resuspended in 0.5 ml ice-cold water, recentrifuged, and the second supemate discarded. This was again
- cupric-triaspartate made with a lower molar ratio of copper to peptide, unexpectedly a dark blue suspension was produced. This was centrifuged and dried under high vacuum over P2O5. On re-exposure to air this gained 11 % in weight from uptake of water. Although this material is eventually soluble in water to the extent of about 2.8 g/L at 37°C, its dissolution is surprisingly slow. Cupric peptides with slow dissolution can be especially useful for inclusion in food or multivitamin-mineral preparations.
- Example N Choline-l,l,l-triaspartate To 5.0 ml of an aqueous 60 mM solution of l,l,l-triaspartic free acid was added 0.77 ml of 20 % choline in water (1.3 mmoles) to give a solution of pH 5.1. This was rotary evaporated to near dryness under reduced pressure, and put under high vacuum over P 2 0 5 to give an off white powder. On exposure to ⁇ 50 % RH, this material became a thick oil in less than 24 hours.
- Example O Choline-1, 1,1-triaspartate on microcrystalline cellulose To all of the oily choline- l,l,l-triaspartate from Example M was added 1 ml water, mixed, a weight of USP grade microcrystalline cellulose was added in an amount equal to twice the initial dry weight of the choline-1, 1,1-triaspartate, and sonicated. This was rotary evaporated to near dryness under reduced pressure at 37 C, and put under high vacuum over P 2 0 5 to give an off white powder. Although this material gained weight on exposure to the atmosphere, it remained free flowing and not sticky for several months and even after 24 hours at 90 % RH.
- Example P Ferrous l,l,l-triaspartate.
- well argon sparged 60 mM 1,1,1-triaspartic free acid was added and briefly sonicated under argon to give a light orange solution of pH 5.4, which was rotary evaporated at 26 C to near dryness under reduced pressure, and put under high vacuum over P 2 0 5 to give light orange brown flakes.
- this material gained 13 % in weight over several days and became dark brown due to partial oxidation to iron(III).
- material open to air via a drying tube did not change color or significantly oxidize and was still soluble in water.
- Example Q A multivitamin-mineral supplement containing 0.125 mmole triaspartate (56 mg of tetrasodium triaspartate on 56 mg of microcrystalline cellulose), 2 mg of copper (as cupric sulfate), 18 mg of iron (as ferrous fumerate), calcium carbonate (300 mg as elemental calcium), caffeine, magnesium oxide, ascorbic acid, guarana seed powder, crospovidone, beta-carotene, biotin, cholecalciferol, chromium chloride, croscarmellose sodium, cyanocobalamin, d-calcium pantothenate, dl-alpha-tocopheryl acetate, fd&c blue #1 lake, fd&c red #40 lake, fd&c yellow #5 (tartrazine) lake, folic acid, hydroxypropyl methylcellulose, manganese sulfate, niacinamide, phytonadione, polyethylene glycol
- compositions is not limited by this particular list.
- Each of the nutrients can be present in a wide range of forms (for example vitamin B 12 as
- cyanocobalamin or methylcobalamin or adenosylcobalamin in a wide range of weights (for example, vitamin B12 from less than 1 microgram or to more than 5 mg) as is common in the art of vitamin formulation. Nutrients can be omitted from the list, or further components added.
- Example S A hair shampoo containing water, sodium lauryl sulfate, sodium laureth sulfate, cocamidopropyl betaine, sodium citrate, sodium xylenesulfonate, fragrance, sodium chloride, citric acid, sodium benzoate, hydroxypropyl methylcellulose, panthenol, panthenyl ethyl ether, methylchloroisothiazolinone, methylisothiazolinone and tetra-sodium-l,l,l-triaspartate in a concentration of about 1.1 mM (-0.05% w/w).
- Example T A hair conditioner containing water, cetyl alcohol, stearamidopropyl dimethylamine, stearyl alcohol, quatemium-l8, fragrance, bis-aminopropyl dimethicone, benzyl alcohol, cetearyl alcohol, hydroxypropyl guar, glyceryl stearate, citric acid, polysorbate 60, panthenol, panthenyl ethyl ether, oleyl alcohol, methylchloroisothiazolinone, methylisothiazolinone and tetra-sodium- l,l,l-triaspartate in a concentration of about 0.05% w/w.
- Example V A hematinic formulation containing 110 mg iron as ferrous fumarate (611 % of the U.S. Daily Value for iron), 60 mg vitamin C as ascorbic acid (100 % DV), microcrystalline cellulose, magnesium stearate, calcium phosphate, and 100 mg of a mixture of Asp- Asp, Asp- Asp- Asp, Asp-Asp- Asp- Asp as a neutralized potassium salt (where Asp- Asp- Asp constitutes >50 mol % of the total).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compositions of foods, vitamin and mineral supplements, topical or oral drugs, and cosmetic products containing a small peptide or peptides for slowing degradation, for example by transition metals. The peptides are di, tri, terra-, and/or penta-peptides containing two or more aspartic acid residues. The degradation of several of the vitamin and other constituents vitamin-mineral supplements can be considerably slowed by composition incorporating such peptides, particularly if soluble (and thus bioavailable) forms of copper and/or iron are also present. The peptides can be hydrolyzed by the normal digestive process thus releasing bound metals. Multiple aspartate peptide(s) compositions with foods, topical or oral drugs, cosmetic, and hair care products can replace synthetic chelating preservative agents. Methods are also described to effectively slow degradation and preserve the above products using multiple aspartate peptides.
Description
PEPTIDE COMPOSITIONS FOR SLOWING DEGRADATION OF VITAMIN- MINERAL SUPPLEMENTS, FOODS, PHARMACEUTICALS, AND COSMETICS
Inventors: Steven W. Bailey and June E. Ayling
FIELD
The present technology is related to peptide compositions for slowing the degradation of vitamin-mineral supplements, foods, pharmaceuticals, and cosmetics, as well as methods of making and using such compositions. The present peptide compositions include short two to five residue peptides having at least two aspartic acid residues.
BACKGROUND
Deficiencies in mineral nutrients are a major contributor to world- wide burden of poor health. Consumption of mineral supplements can be a large contributor to intake, especially in the Western diet. Essential trace minerals are often combined with single vitamins or in
multivitamin-mineral preparations. Among these minerals are several that are transition metals having multiple oxidation states such as iron, copper, chromium, and manganese. It has been recognized for many decades that such metals are capable of degrading various vitamins and other nutrients. For example, the presence of copper has been shown to increase the rate of vitamin B12 degradation [Kondo, H et al, J Clin Invest. 1982 70(4):889-98.]. Several transition metals, such as iron and copper, are well known to catalyze the oxidation of ascorbic acid
[Vitamin C in Health and Disease (1997) pp. 59-94. Packer, L., Fuchs, J. (Eds.). Marcel Dekker New York; L.D. Miiller J. Pharm. Biomed. Anal., 25 (2001), p. 985]. The presence of iron and ascorbic acid has been shown to generate hydroxyl radicals in baby food [Almaas, R et al, European Journal of Pediatrics Volume 156, Issue 6, 1997, Pages 488-492]. Moreover, the combination of iron and ascorbic acid has been reported to induce gastric ulcers in rats [Naito Y, et al, Digestion. l995;56(6):472-8].
The problem of oxidative degradation in supplements is exacerbated by the use of soluble forms of copper such as the sulfate salt or amino acid chelates. The catalytic action of copper can be decreased (but not eliminated) by the use of the highly insoluble cupric oxide. However, numerous studies have shown that cupric oxide has extremely low bioavailability [Baker DH. Cupric oxide should not be used as a copper supplement for either animals or humans. J Nutr. 1999 129(12):2278-9]. Although many multivitamin-mineral supplements are formulated with cupric oxide, this does not provide the copper needed by humans or animals. It is apparent that
manufacturers include this ineffective form in order to avoid the destruction of the other product components as demonstrated above.
Despite the considerable problems associated with directly combining iron and/or copper with other sensitive micronutrients, such as vitamins, there is currently no technology to alleviate the degradation that occurs not only within the product during storage, but also after consumption or during dissolution testing (which is often designed to simulate consumption).
Many foods, topical or oral drugs, and cosmetics are stabilized against degradation by inclusion of EDTA (ethylenediamine tetraacetic acid). EDTA inhibits rancidity (disagreeable odor or taste of decomposing oils or fats) in salad dressings, mayonnaise, sauces, and other foods. It also promotes color retention. This chelating agent has a very high affinity for many metals, and is considered to be safe for use in certain foods within concentration ranges specified by the FDA and other national regulatory agencies. It is also used in topical or oral drugs, and cosmetics. EDTA also has antimicrobial and antibiofilm activities. Moreover, it potentiates other antimicrobials for example those used in wound care. However, although about 5 % of oral intake is absorbed, it is not metabolized by the body, and administration of high levels of EDTA can lead to reduced blood calcium and increased urine calcium. Moreover, it is a persistent environmental pollutant, especially if complexed to metal. Non-biodegradable chelating agents such as EDTA also increase the difficulty of metal removal from waste streams.
SUMMARY
Small peptides containing two or more aspartic acid residues (multiple aspartate peptides) been discovered that slow the degradation of vitamins and other nutrients, especially in vitamin- mineral supplements, of foods, topical or oral drugs, and of cosmetics. The peptide or peptides can be premixed with metal or metals as salts, or added to the final product separately from the metals, or both. An advantage of small peptides over traditional chelators (for example, EDTA) is that the small peptides can be hydrolyzed by digestive proteases, thus releasing the metal(s) for subsequent absorption. Moreover, unlike EDTA, these peptides are biodegradable.
Degradation can be slowed by a composition comprising an effective amount of one or more peptides or a pharmaceutically acceptable salt thereof, wherein each peptide has two to five amino acid residues and at least two of the residues are aspartic acid residues; one or more physiologically acceptable minerals or other physiologically acceptable agents capable of degrading one or more nutrients or drugs; and one or more nutrients and/or drugs sensitive to
degradation by the physiologically acceptable minerals or other physiologically acceptable agents; wherein the one or more peptides preferably do not contain histidine.
A composition comprising an effective amount of one or more peptides or a pharmaceutically acceptable salt thereof, wherein each peptide has two to five amino acid residues and at least two of the residues are aspartic acid residues; one or more physiologically acceptable minerals comprising at least copper and/or iron; and one or more nutrients and/or drugs sensitive to degradation by the copper and/or iron; wherein the one or more peptides preferably do not contain histidine is preferred.
A composition comprising an effective amount of one or more peptides or a pharmaceutically acceptable salt thereof, wherein each peptide has two to five amino acid residues and at least two of the residues are aspartic acid residues; one or more minerals; one or more nutrients and/or drugs sensitive to degradation or color change by said one or more physiologically acceptable minerals; wherein the effective amount of peptide is sufficient to decrease the rate of degradation of the one or more nutrients and/or of color change and/or drugs by at least 5% is also preferred.
An example of a method for decreasing the rate of decomposition of nutrients in vitamin-mineral products and/or drug products during ingestion and/or dissolution testing comprises
incorporation of an effective amount of one or more peptides or a pharmaceutically acceptable salt thereof, wherein each peptide has two to five amino acid residues and at least two of the residues are aspartic acid residues; wherein the one or more peptides preferably do not contain histidine.
An example of a cosmetic or hair-care product composition comprises a topical carrier and the an effective amount of one or more peptides or a pharmaceutically acceptable salt thereof, wherein each peptide has two to five amino acid residues and at least two of the residues are aspartic acid residues; wherein the one or more peptides preferably do not contain histidine.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows the amount of ascorbate recovered (expressed as a percentage of the labeled content) from USP type 2 dissolution experiment containing a commercially available multivitamin-mineral supplement (la) in the absence and presence of 0.25 mM Asp- Asp or Asp- Asp- Asp over time..
FIG. 2 shows the oxygen consumption during dissolution of multivitamin-mineral supplement la over time in the absence and presence of 0.25 mM or Asp- Asp- Asp.
FIG. 3 shows the amount of thiamine recovered at 45 minutes (expressed as a percentage of the labeled content) from a USP type 2 dissolution experiment containing a commercially available multivitamin-mineral supplement (la) in the absence and presence of 0.25 mM Asp- Asp or Asp- Asp- Asp over time.
FIG. 4 shows the half-life of 5-methyltetrahydrofolate as a function of Asp-Asp-Asp
concentration in a homogenous air equilibrated solution of 0.15 mM CuS04 in 10 mM HEPES pH 7.2 at 37 C.
FIG. 5 shows the loss of 5-methyltetrahydrofolate in a homogenous air equilibrated solution of 3 mM ferrous iron in MES buffer pH 6.2 at 37 C in the absence and presence of 3 mM Asp- Asp- Asp tetrasodium salt.
FIG. 6 shows the loss of ascorbic acid, folic acid, thiamine and vitamin B12 all together in a homogenous air equilibrated solution of 150 micromolar cupric sulfate in MES buffer pH 6.2 at 37 C in the absence and presence of 3 mM Asp- Asp- Asp tetrasodium salt.
DETAILED DESCRIPTION
The compositions of the present technology are a food, a vitamin and mineral supplement, a topical drug, an oral drug, a cosmetic, or hair care product and one or more multiple aspartate peptide(s), wherein said peptide is present in an amount capable of slowing degradation of said food, a vitamin-mineral supplement, topical drug, oral drug, cosmetic, or hair care product. Di-, tri, tetra and penta-peptides are preferred. Additional acidic residues in these multiple aspartic acid peptides are such as glutamic acid, sulfonated amino acids, phosphorylated amino acids, and gamma-carboxy-glutamate can also increase effectiveness. Examples of multiple aspartate peptides are, but are not limited to, diaspartic acid, and tripeptides, tetrapeptides, and
pentapeptides that contain at least two residues of aspartic acid. Mixtures of different peptides are also useful such as those having different sequences. It is preferred that at least one of the peptides in such a mixture contain at least two aspartic acid residues. Multiple aspartate peptides can be predominately of one chain length, or mixtures of different lengths. One example is a mixture of diaspartic acid, triaspartic acid, tetraaspartic acid, and pentaaspartic acid. For such mixture it is preferred that the most abundant form be triaspartic acid. The
compositions and methods described herein are suitable for both human and animal use, where the latter includes, among others, cats, dogs, cows, sheep, pigs, and poultry.
In the present disclosure, the phrases“diaspartic acid,”“triaspartic acid,”“tetraaspartic acid” and “pentaaspartic acid” or salts thereof (such as calcium diaspartate) refer to peptide sequences of aspartic acid, e.g. Asp- Asp, Asp- Asp- Asp, Asp-Asp-Asp- Asp, Asp-Asp-Asp- Asp- Asp, and calcium Asp-Asp, respectively. They do not refer to separate (non-covalently linked) amino acids. For example, in the present disclosure, calcium diaspartate does not signify a salt of calcium containing two separate (non-covalently bound) aspartic acid molecules (CAS:
39162-75-9) that are not linked together into a peptide.
For multiple aspartate peptides having more than two amino acids, those which are not aspartic acid can be any of the amino acids found in proteins, for example, glutamic acid, (which is especially preferred), glycine, alanine, valine, leucine, isoleucine, serine, cysteine,
selenocysteine, threonine, methionine, proline, phenylalanine, tyrosine, tryptophan, lysine, arginine, asparagine, and glutamine, but preferably not unmodified histidine. Post- translationally or otherwise naturally modified amino acids can also be used. Many such modifications are known to the art. Examples that can be used with the methods and
compositions described herein include, but are not limited to, phosphorylated amino acids (e.g., phosphoserine, phosphothreonine, phosphotyrosine, phosphoaspartic acid, phosphoglutamic acid, phosphohistidine, phosphocysteine, etc.), gamma-carboxy-glutamate, pyrrolysine, selenocysteine, hydroxylated amino acids (e.g., asparagine, aspartic acid, proline, lysine, etc.), alkylated amino acids (e.g., methylated forms of histidine, lysine, glutamic acid, etc.), sulfonated amino acid (e.g., serine, threonine, tyrosine, etc.), citrulline, N- and O-glycosylated amino acids. For peptides containing only aspartyl residues, triaspartic acid is preferred, although
tetraaspartic acid is just as effective on a molar basis. Tetraaspartic acid has a higher molecular weight and potentially requires additional synthetic steps than triaspartic acid. Ala- Asp-Asp was found to be about half as effective on a molar basis as triaspartic acid, although its lower molecular weight makes up for some of this difference on a per weight basis. Examples are Asp- Asp-Glu, Asp-Glu-Asp, Glu-Asp-Asp, Asp-Asp-Ala, Asp-Asp-Glu, Asp-Asp-Asp-Glu, Asp- Asp-Ala, Ala-Asp-Asp-Asp, Gly-Asp-Asp, Asp-Asp-Cys, Asp-Asp-Met and others some of which are listed in Table 1.
Table 1
While peptides containing residues that are fully or partially racemic (due to the nature of the starting materials or by racemization during synthesis) can be effective, it is preferred that the peptides be substantially chiraly pure at each position in the sequence. By Asubstantially®, it is meant that chiral purity of the residue in each position be greater than 80 %, or more preferably greater than 90 %, and most preferably greater than 95 %. The peptides can have some residues which are the substantially pure L-isomer, and contain other residues which are the substantially pure D-isomer. Peptides made of some or all residues that are predominately the unnatural D- isomers can also inhibit metal catalyzed oxidation reactions. Those made primarily of the natural amino acid L-isomers are capable of being proteolyzed in the digestive track, which thus liberates the bound metals to be more quickly absorbed into the blood than those containing D- isomers. Most animals including humans are exposed to some amount of D-amino acids (which can be detected in blood and urine). In particular, D-aspartic acid is biosynthesized in the human
brain. Thus, the rate of proteolysis can be controlled by inclusion of a D-amino acid as part of the multiple aspartate peptide.
The degradation of vitamins, foods, topical or oral drugs, cosmetics, or hair is often due to the presence of transition metals. These can be explicitly added, such as in vitamin-mineral supplements. Compositions that are do not contain explicitly added transition metals whether a vitamin, food, a topical or oral drugs, or cosmetic can still benefit from increased stability by combination with peptides due to the presence of trace or unquantified metals. Moreover, hair itself often contains significant bound metal (such as copper or iron) that affect its properties.
Uptake of a metal from the intestinal tract can be influenced by the several factors controlled by the peptides to which it is bound. Moreover, clearance of peptides from the digestive tract can occur by several mechanisms. For example, the peptide can be proteolyzed into its amino acid constituents which will have lower affinity for the metal, allowing for its subsequent uptake into the enterocyte. Uptake of transition metals can enhance stability of the other sensitive nutrients still remaining in the intestinal tract. In addition, a considerable portion of the total intestinal uptake of amino acids occurs in the form of di- and tri-peptides, which are substrates for several peptide transporters as well as by a paracellular route. The use of a small peptide to quench the redox activity of the transition metals present in a food or supplement has the advantages over other chelating agents in being ultimately digestible and exposing the consumer only to natural products. The selection of the amino acids in the peptide which are not aspartic acid can, in part, be tailored to a give an optimal rate of proteolysis in the digestive tract. This, in turn, can modulate the release of the bound transition metals.
The sequence Asp- Asp- Asp (single letter code: DDD) is found naturally within many larger proteins in microbes and eukaryotes. For example, this is found in within lactalbumin, caspase 3, and coagulation factor VIII. The sequence Asp- Asp- Asp- Asp (DDDD) has been found among the peptides contained in hydrolyzed beer yeast Thus, humans have long been exposed to similar peptides resulting from digestion of dietary protein indicating that they are safe for consumption. Large proteins in of themselves are, however, not efficient for use in vitamin preparations even if they both bound metal and hindered its redox reactions due to their much high molecular weights.
Although most peptide amide linkages are made through the alpha amino and carboxyl groups, peptides linked via the beta carboxyl group of aspartic acid, the gamma carboxyl group of
glutamic acid, and/or the epsilon group of lysine can also be useful for controlling the redox activity of transition metals. Glutathione and folate polyglutamic acids illustrate some naturally occurring peptides with gamma-linkages. Peptides containing such linkages are still capable of being cleaved by proteases. Examples of a multiple aspartate peptides containing a beta-linkage are a-Asp-p-Asp, a-Asp-a-Asp-P-Asp, a-Asp-P-Asp-a-Asp, and a-Asp-P-Asp-X, where X is another amino acid as described above. The inclusion of a hydrophobic residue (for example, valine, leucine, isoleucine, methionine, or phenylalanine) can aid, among other things, the isolation and purification of the peptide after its synthesis. The ability of l,l,l-triaspartic acid to inhibit oxidative destruction of other multivitamin components was found to be dependent on the presence of a free N-terminal amino group as determined by the lack of effectiveness of N- acetyl-l,l,l-triaspartic acid.
The ratio of metal, metals, and/or other cations such as choline to the multiple aspartate peptide, in vitamin-mineral or other nutritional product, topical or oral drug product, or cosmetic product can be variable. More relevant to effectiveness in preventing product degradation is the total amount of the multiple aspartate peptide or multiple aspartate peptides. For vitamin-mineral products the preferred range of peptide can be based on the mole amount in the product composition that minimized degradation both on the shelf and during digestion or dissolution testing. For food, topical or oral drugs, and cosmetic products minimization degradation during the shelf life is of particular importance.
An appropriate way of determining degradation during digestion, for example of vitamin-mineral compositions is through the use of dissolution methods, for example as set forth in the U.S. Pharmacopeia. As the amount of transition metals (for example, copper or iron) capable of promoting degradation (such as redox reactions) increases, the mole amount of peptide needed to achieve a particular level of stabilization can also increase. For example, with a vitamin-mineral product containing the U.S. Daily Value of a soluble form of copper (2 mg as the elemental weight, 31.5 micromole per serving size), useful amounts of, for example, triaspartic acid (as the total of all salt or acid forms) can be between about 0.01 millimoles to about 3 millimoles per serving size (for example, 0.01 mmole, 0.02 mmole, 0.03 mmole, 0.04 mmole, 0.05 mmole, 0.06 mmole, 0.07 mmole, 0.08 mmole, 0.09 mmole, 0.1 mmole, 0.15 mmole, 0.2 mmole, 0.25 mmole, 0.3 mmole, 0.4 mmole, 0.5 mmole, 0.6 mmole, 0.7 mmole, 0.8 mmole, 0.9 mmole, 1.0 mmole, 1.1 mmole, 1.2 mmole, 1.3 mmole, 1.4 mmole, 1.5 mmole, 1.6 mmole, 1.7 mmole, 1.8 mmole, 1.9 mmole, 2.0 mmoles, 2.25 mmoles, 2.5 mmoles, 2.75 mmoles, 3.0 mmoles per
serving size). The serving size is that quantity of product indicated on the product label that when consumed per occasion delivers the labeled nutrients. A serving size for a vitamin mineral product, for example, might be one tablet or capsule, but also can be labeled as two or more tablets or capsules. In specifying a mole amount of a peptide mixture, the above range refers to the amount of each individual peptide. Other multiple aspartate peptides can require different total amount to achieve similar effectiveness (as can be judged, for example, by USP dissolution experiments). For example, the mole amount of Ala-Asp- Asp needed is about twice that of Asp- Asp-Asp to provide similar effectiveness. With a lower amount of added transition metal, e.g. copper, the total amount of added peptide can be lower to produce a desired level of product stability. It should, thus, be appreciated that an important factor is the total amount of the peptide or peptides in the composition, regardless of which salt or acid forms are added in relation to the amount of transition metals present. The amount of a peptide contained in a vitamin-mineral product for the purpose of slowing its degradation can be specified by the total moles of peptide in a serving size. This is more informative than specifying only its ratio to of any of the potentially several metals in the product. Moreover, the optimal amount depends on the particular constituents of the vitamin-mineral or other nutritional product since the presence of high concentrations of some metals can decrease the effectiveness by competition for binding of the peptide or peptides even if not promoting degradation in of themselves. The optimal amount can be determined by dissolution or other stability assays for each product formulation. The effective amount of a multiple aspartate peptide or peptides in a composition is that that which can slow the rate of degradation by at least than 5 %, preferably at least 10 %.
For food, topical or oral drug, and cosmetic compositions the amount of peptide is preferably given as the molar concentration. The difference between specifying the mole amount given for a vitamin-mineral supplement composition versus a molar concentration for the food, topical or oral drug, or cosmetic composition is due to the need for slowing the degradation of the former occurring after dissolution into a certain volume of either digestive juices or into a simulating test thereof. With food, topical or oral drug, and cosmetic compositions the degradation (such as oxidation, discoloration, development of rancidity, or by microbial contamination) is primarily desired to be slowed during storage, in which case the volume of the product is approximately known, and a concentration can be specified. While many of these products do not have transition metals added explicitly as an ingredient, they still contain such metals that are endogenous to, or are contaminants of the other ingredients. A hair care product can, in addition, protect the hair from copper, iron, or other metals already bound within the hair. For
food, topical or oral drug, cosmetic and hair compositions this concentration can be between about 0.02 mM and about 6 mM (for example 0.02 mM, 0.03 mM, 0.04 mM, 0.05 mM, 0.06 mM, 0.07 mM, 0.08 mM, 0.09 mM, 0.1 mM, 0.15 mM, 0.2 mM, 0.25 mM, 0.3 mM, 0.4 mM, 0.5 mM, 0.6 mM, 0.7 mM, 0.8 mM, 0.9 mM, 1.0 mM, 1.1 mM, 1.2 mM, 1.3 mM, 1.4 mM, 1.5 mM, 1.6 mM, 1.7 mM, 1.8 mM, 1.9 mM, 2.0 mM, 2.25 mM, 2.5 mM, 2.75 mM, 3.0 mM, 2.25 mM, 3.50 mM, 3.75 mM, 4.0 mM, 4.25 mM, 4.50 mM, 4.75 mM, 5.0 mM, 5.25 mM, 5.50 mM, 5.75 mM, 6.0 mM) in the example of the peptide being triaspartic acid. For a product that is in a packing medium, for example canned beans, the volume used for calculating the added the multiple aspartate containing peptide is the combination of the product and the packing medium. The multiple aspartate peptide or peptides can conveniently be added first to the liquid packing medium, or to the combination of the medium with the product. For example, a product having a total (product plus medium) volume of 8 fluid ounces (237 mL) would contain between about 0.005 mmoles and 1.4 mmoles of, for example, triaspartic acid to achieve the above
concentration range. A one ounce product would contain between about 0.6 micromoles and 177 micromoles. Due to the large variability of potential product weights for food, topical or oral drug, cosmetic or hair compositions, it is thus clear that a molar concentration is more meaningful than a mole amount (the latter being more appropriate for the above vitamin-mineral compositions. Multiple aspartate peptides other than triaspartic acid can require different molarities to achieve similar effectiveness in slowing degradation. For example, the
concentration of diaspartic acid needed to achieve an effectives similar to triaspartic acid can be about twice those described above in this paragraph for triaspartic acid. In specifying a molar concentration of a peptide mixture, the above range refers to the concentration of each individual peptide. Peptides have several advantages over commonly used preservatives, such as EDTA (ethylenediamine tetraacetic acid). The peptides of this invention when taken orally are, unlike EDTA, digested to amino acids which can be utilized by the body=s normal metabolism.
Moreover, even if not ingested, these can be broken down by natural processes, which is an advantage for products such as shampoos and conditioners that are largely washed into sewage systems.
For several of the products herein described the improvement in the stability of the components with increasing multiple aspartate peptide was discovered to follow a asymptotic curve. For example, for one particular product, the amount of tetrasodium l,l,l-triaspartate in a USP type 2 dissolution experiment required to give half of the maximal stability of the ascorbic acid component of a particular multivitamin-mineral product was about 11.3 mg (0.025 mmoles
peptide in a 0.5 L test volume). A greater level of stabilization can be achieved with a higher amount of peptide, but at the expense of increased product weight. It can be appreciated that since the total weight/size of a vitamin-mineral tablet or capsule, etc. is limited, it can be advantageous to have any counter-ion associated with the multiple aspartate peptide or peptides have more nutritional value than sodium (for example, potassium or magnesium), though sodium is effective. The free acid can be used preferably if appropriately neutralized during dissolution by the other product components.
The ability of multiple aspartate peptides to hinder oxidation is decreased in acidic conditions. Therefore, it is preferred that the pH of a vitamin-mineral product containing a multiple aspartate peptide should be above about pH 6 upon dissolution. Since the free acid form of the multiple aspartate peptides can contribute to the overall acidity, this can be converted to a more neutral salt form or forms. Alternatively, the presence of alkaline substances in the vitamin-mineral product, for example calcium carbonate or magnesium oxide, can be used to adjust the pH to be in the optimal range once dissolved. The copper present in a vitamin-mineral product can be added as a preformed salt with a multiple aspartate peptide, or formulations where the multiple aspartate peptide is added as a different salt form, or as a combination with other salt forms in addition to that with copper. Other salt forms of the multiple aspartate peptides include sodium, potassium, magnesium, and calcium, or any other metal to be added to the vitamin-mineral product. The magnesium or calcium salts are particularly useful since these often are present as a considerable percentage of the total weight of the final product. When the multiple aspartate peptide is used in substitution for the carbonate, citrate, fumarate, or other counter-ions often accompanying these metals, the extra weight due the peptide is offset by that which would otherwise be present. For example, including 52.5 mg of Cars-U, 1-triaspartate (not counting any water of hydration) would provide 0.125 mmol of l,l,l-triaspartate and 7.5 mg of elemental calcium. Had this amount of calcium instead been included in the form of its citrate salt, this would have added about 31 mg (not counting any water of hydration). In this case, product weight increases only about 21 mg per dose by the substitution of triaspartate for citrate.
Since as mentioned above, the effectiveness of multiple aspartate peptides is optimal above about pH 6, some dosage formulations can benefit from enteric coatings, or other strategies that as are well known in the industry, that delay dissolution until after any stomach acid has been neutralized by the digestive tract.
The metals in a vitamin-mineral product can be present either in a salt form well understood to the art of such products, or as metal-peptide complex, or both. For example, copper is typically present in products as cupric sulfate, cupric oxide, cupric citrate, cupric acetate, copper sebacate, cupric bis-glycinate and other amino acid chelates, and the like. Iron is typically present in products as ferric oxide, ferrous fumerate, ferrous sulfate, ferric phosphate, ferrous bisglycinate chelate, carbonyl iron, ferrous succinate, ferrous aspartate, ferrous gluconate, micronized elemental iron, and as a hydrolyzed protein complex. These can be present as such salt(s) or chelates along with multiple aspartate peptide(s) (either as a free acid and/or as the salt of a different metal (such as potassium, sodium, magnesium or calcium, etc.), or as a copper or iron salt of a multiple aspartate peptide, or both. Multiple aspartate peptide salts of yet other transition metals are also useful.
Transition metals essential for mammalian life with multiple valence states where inclusion of a peptide can be advantageous in controlling product degradation include vanadium, chromium, manganese, iron, cobalt, nickel, copper, and molybdenum. These metals are often added, along with other metals, to vitamin-mineral products. Iron and copper can be especially problematic due, in part, to their high amounts in multivitamin-mineral products. Other transition metals can be found in multivitamin products or foods that are not essential for mammalian life, but which can in any case cause degradation of components of the multivitamin product or the food, and which can benefit from inclusion of a multiple aspartate peptide. In addition, zinc is another essential transition metal that is present in a large amount (U.S. Daily Value 15 mg) in many vitamin-mineral products. Although ionic zinc has only a single valence state (+2), it none the less is known to catalyze, or co-catalyze with other metals, oxidation reactions.
It was found that the salts of several peptides such as multiple aspartate peptides can be hygroscopic to the point of becoming sticky in high humidity environments. It was also discovered that combining such hygroscopic compounds with certain matrices, while not necessarily preventing uptake of water, can none the less produce a novel composition that unexpectedly can be easily handled. One such matrix is microcrystalline cellulose which is commonly used as an excipient in vitamin and mineral products. A method of combining the peptide salt with the excipient was also developed in which the former is dissolved in a suitable solvent, for example water, the excipient added with stirring, and removing the solvent from the mixture, for example by rotary evaporation under reduced pressure or lyophilization. The weight ratio of matrix to the peptide salt can be between about 0.1 to 10, preferably 0.2 to 2. The
resulting solid can then be crushed to give the appropriate particle size (for example between 100 and 400 mesh) for homogeneous distribution when added to the other vitamin and mineral ingredients. Other examples of matrices useful for making more easily handled peptide compositions include powdered cellulose, cellulose, kaolin, talc, silica and silicic acid.
Compositions containing the di, tri, tetra or penta-multiple aspartate containing peptide or peptides can also include nutrients and foods that do not necessarily contain explicitly added transition metals (such as iron or copper), but which contain such metals endogenous to food ingredients. In addition, appropriate foods are also those to which a transition metal has been added. The amount of peptide in the composition is that which significantly inhibits degradation (for example, by oxidation, discoloration, or microbial accumulation). Examples of foods which can contain the peptide are, but are not limited to, baby foods and infant formula, ready to eat cereals, formulated bars (such as energy bars), pickled cabbage, carbonated soft drinks, white potatoes (for example canned or frozen), clams (for example canned), crabmeat (for example canned), pickled cucumbers, alcoholic beverages, dressings (such as salad dressing), egg products, fermented malt, beverages (examples: any fruit juice, flavored water containing ascorbic acid), legumes (for example, black-eyed peas, canned lima, pinto, kidney, garbanzo, pink or red beans), mayonnaise, mushrooms (for example canned), oleomargarine, pie filling (for example pecan or strawberry), potato salad, sauces, shrimp, spice extractives in soluble carriers, spreads (for example sandwich spread), fish (for example Gefilte fish). Foods that are high in water are especially appropriate. However, even relatively dry foods can benefit by diminishing the metal catalyzed reactions. Examples of such a multiple aspartate peptides are diaspartic acid, triaspartic acid, and tetraaspartic acid, and their salts as described above. Multiple aspartate peptide or peptides containing amino acid residues other than aspartate, such as those described above, can also be useful.
Compositions containing the di, tri, tetra or penta-peptide or peptides containing two or more aspartates can also be antimicrobial formulations wherein the peptide or peptides are a potentiating and/or sensitizing agent for other antimicrobial compounds. Such formulations can be used for wounds, suture materials, contact lenses, intraocular lenses and the like. These peptide or peptides can be combined with other antimicrobials such as benzalkonium chloride, cetylpyridinum, chloramphenicol, chloroxylenol, chlorohexidine, imipenem, oxytetracydine, penicillin, polymyxin B sulfate, tricolsan among others. Such antimicrobial formulations can be
effective against Gram-negative, Gram-positive bacteria, amoeba, fungi and yeasts, and can be used to help prevent and/or decrease biofilm development.
Nutrient product compositions for which multiple aspartate peptides can be effective range from those containing only a single nutrient (for example, a vitamin) and a single transition metal (for example iron or copper) to more complex multi-nutrient and/or multi-metal compositions. An example of a product to which multiple aspartate peptide(s) can be incorporated having two active ingredients is a hematinic containing vitamin C and a form of iron such as those listed above. Hematinic products often contain additional nutrients such as a folate (e.g., folic acid, 5- methyltetrahydrofolate, 5-formyltetrahydrofolate) and vitamin B12 among others. These nutrients, like the ascorbic acid in the simpler formulation, can be protected by the inclusion of multiple aspartate peptide(s). Multiple aspartate peptide(s) can be a component of more complex compositions such as multiple vitamin-mineral products containing numerous vitamins and other nutrients (such as amino acids, proteins, nucleic acids, or unsaturated lipids), or micronutrients, (such as carotenoids, e.g. beta-carotene, lycopene, lutein, zeaxanthin, and astaxanthin; polyphenols, e.g. anthocyanidins, catechins, flavonoids, tannins, and procyanidins; and cofactors, e.g., coenzyme Q and glutathione) many of which are susceptible to oxidative degradation, for example by iron or copper. Multiple aspartate peptide(s) can be a component of a multiple vitamin-mineral composition that in addition include natural products or foods as extracts or powders or oils, or any product sold as a supplement. The form of these
compositions include, but are not limited to, pills, tablets, capsules, caplets, powders, gels, gummies, chews, effervescents, lozenges, confectionery, etc. While some of these are solid products, others are liquid compositions, examples of which are liquid vitamin products, syrups, mouthwashes, suspensions, complete diets, infant diets, dietary supplements and weight loss products.
Among the vitamins that can components of the multiple vitamin-mineral products of this invention are vitamin C (ascorbic acid and/or its salts), vitamin A (in its various forms such as retinyl acetate, retinol, retinyl palmitate, retinal, vitamin A precursor carotenes, e.g. beta- carotene), vitamin B7 (e.g., biotin), vitamin D (in its various forms such as cholecalciferol, ergocalciferol), 25-hydroxycholecalciferol, 25-hydroxyergocalciferol), vitamin B12 (in its various forms such as cyanocobalamin, methylcobalamin, adenosylcobalamin,
hydroxycobalmin), vitamin B5 (in its various forms such as pantothenic acid, calcium
pantothenate, and the provitamin pantothenol), vitamin E (in its various forms such as alpha,
beta, gamma or delta-tocopherols or mixtures thereof, and/or alpha, beta, gamma or delta- tocotrienols, or mixtures thereof, as well as esters of these such as tocopheryl acetate), vitamin B9 (folate in its various forms such as folic acid, 5-methyl-tetrahydrofolic acid, 5-formyl- tetrahydrofolic acid, 10-formyl -tetrahydrofolic acid, 5,l0-methylene-tetrahydrofolic acid, 5,10- methenyl-tetrahydrofolic acid, 5-formimino-tetrahydrofolic acid, tetrahydrofolic acid), vitamin B3 (in its various forms such as niacinamide, nicotinic acid, nicotinamide riboside as well as biomolecules incorporating these such as nicotinamide adenine dinucleotide and its derivatives NADP, NADPH, and NADH), vitamin K (in its various forms such as Kl (e.g.,
phytomenadione), and K2 (e.g., menaquinones)), vitamin B6 (in its various forms such as pyridoxine, pyridoxine-5 '-phosphate, pyridoxal-5 '-phosphate, and pyridoxamine), riboflavin (as well as its enzymatically active forms flavin mononucleotide and flavin adenine dinucleotide), and vitamin B1 (thiamine and such forms as its mononitrate and hydrochloride salt, as well as its various phosphate derivatives). Among these, vitamin C, biotin, vitamin A, folate, vitamin B12, vitamin D, vitamin E, and vitamin K, can be especially susceptible to oxidation, particularly if metal catalyzed, for example by iron or copper.
Vitamin-mineral compositions and multivitamin-mineral compositions can in addition to essential and nonessential nutrients also contain excipients that provide a number of useful attributes such as, antiadherents, binders, coatings, colors, disintegrants, flavors, glidants, lubricants, preservatives, sorbents, sweeteners, vehicles. Examples of these include calcium carbonate, magnesium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, microcrystalline cellulose, powdered cellulose, dextrates, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, or mixtures thereof, agar-agar, alginic acid,
croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, clays (such as kaolin and talc), other algins, other celluloses, gums, or mixtures thereof, lactose, sugar, maltitol, gelatin, polyethylene glycol, methyl cellulose, polyvinylpyrrolidone, hydroxypropyl methylcellulose, waxes, shellac, silica, fats (e.g. vegetable stearin), magnesium stearate, stearic acid, and others known to the art.
The present invention also includes a method for stabilizing a food, vitamin, nutrient, or hair from metal catalyzed degradation. The methods involves incorporating an effective amount of multiple aspartate containing di,- tri-, tetra- or penta-peptide or a combination of these into a food, vitamin, or hair-care product. Examples of foods to which the peptides can be added are, but are not limited to, baby foods and infant formula, ready to eat cereals, formulated bars (such
as energy bars), pickled cabbage, carbonated soft drinks, white potatoes (for example canned or frozen), clams (for example canned), crabmeat (for example canned), pickled cucumbers, distilled alcoholic beverages, dressings (such as salad dressing), egg products, fermented malt, beverages (examples: any fruit juice, flavored water containing ascorbic acid), legumes (for example, black-eyed peas, canned lima, pinto, kidney, garbanzo, pink or red beans), mayonnaise, mushrooms (for example canned), oleomargarine, pie filling (for example pecan or strawberry), potato salad, sauces, shrimp, spice extractives in soluble carriers, spreads (for example sandwich spread), fish (for example Gefilte fish). Foods that are high in water are especially appropriate. For a product that is in a packing medium, for example canned beans, the volume used for calculating the added the multiple aspartate containing peptide is the combination of the product and the packing medium. The multiple aspartate peptide or peptides can conveniently be added first to the liquid packing medium, or to the combination of the medium with the product. The method of incorporating multiple aspartate peptide(s) can also be used for any combination of individual foods, such as those that are processed or cooked or baked, as well as those that are not heated. The nutrient can be a macronutrient, such as a protein, carbohydrate, or fat
(especially unsaturated fats), or a micronutrient, (such as carotenoids, e.g. beta-carotene, lycopene, lutein, zeaxanthin, and astaxanthin; polyphenols, e.g. anthocyanidins, catechins, flavonoids, tannins, and procyanidins; and cofactors, e.g., coenzyme Q and glutathione) or essential such fatty acids, essential amino acids, or vitamins). The effective amount of said peptide is that which is sufficient to slow the rate of degradation of at least one vitamin or nutrient component (for example ascorbic acid) or slows the rate of change in color or of microbial contamination by at least 5 %, preferably at least 10 %. Examples of methods of this invention are those where the multiple aspartate peptide is of the type described above, e.g.
diaspartic acid, triaspartic acid, and tetraaspartic acid. The concentration of Asp- Asp- Asp to be incorporated to achieve this level of decreased rate ranges between about 0.02 mM and about 6 mM. Other multiple aspartate peptide(s) can use more or less than this range depending on their effectiveness relative to Asp-Asp-Asp.
In formulating a composition or optimizing a method the rate of degradation for vitamin formulations can be determined in vitro, for example by dissolution methods set forth in the US Pharmacopeia (USP), or by in vivo pharmacokinetic measurements. In the former case, the rate of loss of the vitamin or nutrient itself, and/or the appearance of degradation products can be measured and compared to an identical experiment lacking the peptide. The USP methodology contains numerous procedures for analysis of content or dissolution rates, etc. that are tailored to
the physical form of each product. Among these, for example, Type 1 employs a rotating basket, Type 2 a paddle, Type 3 a reciprocating basket, and Type 4 a flow through cell. In many tests for specific products only a single sample is measured at a specific time. In the context of this invention, samples are analyzed at various times typically over the course of about 120 minutes which encompasses the time of peak absorption of many micronutrients from the digestive tract. Various media such as water, phosphate buffer, simulated gastric fluid, dilute hydrochloric acid, etc. can be used for these test. Some USP tests call for dearation of the medium, but in the context of this invention the medium is best equilibrated to atmospheric oxygen or some other defined mixture of oxygen in another inert gas such as nitrogen. This permits the measurement of the rate of degradation of the components of a product (such as a multiple vitamin - mineral capsule) in a way simulating the influence of consumption by drink a liquid, such as water.
Products that are themselves already in the liquid state can also be examined with these methods, except that dissolution itself is not a factor. The liquid product once thoroughly mixed in the medium can still be agitated, or not, depending on the desire to continue the introduction of further atmospheric oxygen. Tests that are not based on USP methods and/or apparatus can also be used. This is useful when examining small volume of homogenous solutions, especially when testing small quantities of peptides in a small vessel.
Many analytical procedures are known in the art for measuring the amount of a specific nutrient or set of nutrients. Among the most useful are those based on gas or liquid chromatography. Some of these procedures are described in various USP monographs, while many others are published in analytical journals. The rate of degradation of a nutrient can be determined by comparing the amount observed in an early sample taken from the measuring apparatus and comparing this to that observed in a later sample. It can also be determined by comparing the amount observed at a given time after mixing with the test medium in comparison to the amount that is measured to be in the product before dissolution. In the latter case, the product is dissolved in such a way that avoids exposure to oxygen and/or incorporates agents that inhibit product oxidation. For example, the initial content of ascorbic acid in a multivitamin-mineral product can be measured by mixing crushed product in thoroughly deaerated 5 mM EDTA under inert gas, and filtering anaerobically.
The rate of degradation can be calculated by comparing the measured content of a nutrient in samples at a various times with either the initial content as measured above, or the highest value within the run, or with the labeled content of the nutrient. The same calculation is performed the
presence and absence of the peptide, and the ratio of the two measurements is examined for each of the sampling times. For the purpose of determining the effective amount, comparison of the value for the sample time giving the greatest difference between the ratio in the presence vs absence of peptide is preferred.
In the in vivo method, the appearance of the nutrient in the blood or urine, and/or the appearance of degradation products in blood or urine can be measured. For some nutrients, such as ascorbic acid, in vivo pharmacokinetics are difficult to observe at low dose, and in such cases the use of isotope labeled nutrient and/or measurement of degradation products can be advantageous, as is well known in the art of pharmacokinetics. The degradation can be catalyzed by metals that are added to a food or vitamin, or those that are intrinsic to a food. The rate of degradation of foods or nutrients that are not in the form of tablets or capsules or other such concentrated forms, can be examined by the change in individual components, in color, or by microbial contamination over the intended shelf life by analytical methods well known to the art of food and nutrient technology.
The rate of color change can be measured subjectively by matching colors to a standardize chart, or preferably using a colorimeter, spectrocolorimeter, or spectrophotometer as a function of time. The rate of degradation due to increased rancidity can be examined by several tests including the Peroxide Value (PV) which measure the amount of lipid peroxides; the p-Anisidine (p-AV) and Kreis tests which measures the aldehydes/ketones present in lipids; the ThioBarbituric Acid Reactivity (TBAR) test which also measures aldehyde content (especially malondialdehye); and the Oxidative Stability Index (OSI) test which is examines stability to air oxidation under accelerated conditions, frequently using the Rancimat method. These methods can be used in the presences and absence of added multiple aspartate peptide(s) to determine the decrease in rate of degradation.
Multiple aspartate peptides and their salts, especially their alkali and alkaline salts, can also be effective for slowing degradation of cosmetic compositions, for example bath preparations, bath soaps and detergents, fragrance preparations, skin cleansing preparations, moisturizing preparations, deodorants, foundations, aftershave lotion, shaving cream, baby shampoos, bubble baths, body and hand, neck and face preparations, creams, lotions, shampoos, makeup products, lipsticks, eye and facial makeup. Hair has been shown to take up copper and iron from a number of sources, including tap water. This leads to increased oxidative degradation of the hair protein, especially in the presence of UV such as in sunlight. Multiple aspartate peptides and their salts,
especially their alkali and alkaline salts, can be especially useful in cosmetic preparation used on hair, for example hair shampoos, conditioners, dyes, permanent waves, and colors, etc. They can also be effective in topical or oral drugs such as sunscreens, for products regulated both as a cosmetic and drug such as moisturizing sunscreens, and for other dermatologic drugs. These peptides can stabilize and enhance antioxidants such as ascorbate, tocopherol, and retinol frequently used in and topical or oral drug compositions and cosmetic products.
The degradation of hair and its improvement as a result of using hair products containing multiple aspartate peptide(s) can be assessed by a number of measurements known to the art, for example shine, breakage, and combing force, as well as by analytical techniques such as mass spectroscopy. It is preferred that the decrease the degradation of hair as measured by these or other methods be greater than 5 % in comparison to a similar composition lacking multiple aspartate peptide(s).
The multiple aspartate peptides of this invention, whether as salt and/or free acid forms, can be added in powdered solid form to the food, vitamin-mineral supplement, topical or oral drug, or cosmetic. In the case of the vitamin-mineral supplement, this powder can be mixed and made sufficiently homogeneous with the other solid components by the methods well known in the art of pharmaceutical and supplement manufacturing. In the case of foods, topical or oral drug, and cosmetic products having considerable water content, or liquid supplement products such as liquid filled capsules, the added peptide can be dissolved in this water are made homogeneous by mixing. Alternatively, the peptide can be first dissolved in a suitable solvent, for example water or glycerol. The solubility of the peptide, for example a multiple aspartate peptide is increased as a salt form, for example as a sodium or potassium salt.
The effect of transition metals on the degradation (such as by oxidation) of nutrients can, in addition to the inclusion of a multiple aspartate peptide, be further hindered by the use of slowly dissolving form of the metal. The metal can be in the form of a salt with intrinsically low dissolution rate, or a form that is incorporated into a matrix, for example by microencapsulation, as is known to the art of bioavailability manipulation. It should be understood that in establishing the effective rate of dissolution of a slowly dissolving form of the metal according to USP methodology it is preferable to measure this in the presence of the other ingredients in a product, rather than simply by itself in water or buffer. It was discovered that dissolution can be influenced by the other product ingredients, in many cases producing faster rates, for example of copper salts, than in water only. The use of a slowly dissolving form of a
transition metal, for example copper, can further hinder the destruction of nutrients in addition to the inclusion of a multiple aspirate peptide.
EXAMPLES
Synthesis of Aspartic acid peptides
BOC-Asp-Asp-Bii3: L-Aspartic acid dibenzyl ester 4-toluenesulfonate, 9.7 g (20 mmol) was dissolved with brief heating in 12.5 ml anhydrous DMF. To this, now at ambient temperature, was added a solution of 8.4 g (20 mmol) Boc-L-aspartic acid B-benzyl ester
N-hydroxysuccinimide ester in 12 ml anhydrous DMF, followed by 2.8 ml (~ 21 mmol) triethylamine with stirring. A 10-fold dilution of a sample into water measured pH 4.5 with indicator paper. The reaction was followed by injection of a 10-fold dilution into MeOH onto a Prodigy C-18 150 x 4.6 mm HPLC column eluted at ambient temperature with ACN/0.l% TFA (11 :9) at 2 ml/min with photodiode array detection. Analysis at 83 minutes indicated that all of both starting materials had been consumed. Solvent was removed by rotary evaporation at reduced pressure, 60 ml of ethyl acetate added, the resulting solution washed with 3 x 75 ml of water. Solvent was removed by rotary evaporation at reduced pressure and the product dried under high vacuum over P205 to give 11.6 g of BOC-Asp-Asp-Bn3 as a light tan powder.
Asp-Asp-Bn3: All of the above BOC-Asp-Asp-Bn3 was dissolved in 20 ml of anhydrous dimethoxyethane under a blanket of inert gas and placed on ice. To this was quickly added 25 ml of HC1 in anhydrous dimethoxyethane (saturated by 45 minutes of bubbling HC1 on ice) with vigorous stirring. After 45 minutes the reaction was removed from the ice and allowed to warm to room temperature. HPLC as above indicated complete disappearance of starting material by 115 min. Solvent was removed by rotary evaporation at reduced pressure with two further additions of 25 ml each of fresh DME to facilitate removal of HC1, and the solid kept under high vacuum over NaOH pellets to give a thick orange oil that solidifies on storage.
BOC-Asp-Asp-Asp-Bn-»: All of the above Asp-Asp-Bn3 was dissolved in 10 ml anhydrous DMF to which was added 8.0 g Boc-L-aspartic acid B-benzyl ester N-hydroxysuccinimide ester in 11 ml anhydrous DMF. The reaction was initiated by titration with Et3N to pH 4.5 to 5.0 (sample 10-fold diluted in water measured with indicator paper), and stirred at room
temperature. The pH is maintained within this region using additional Et3N. After 2 hours consumption of reactants is near completion as indicated by HPLC of a 50-fold dilution in
MeOH using the above system, but with ACN/0.l% TFA (1 :2), while product is eluted more rapidly with a 53:47 solvent ratio. Solvent was removed by rotary evaporation at reduced pressure to give a thick slurry which was dissolved in 60 ml of ethyl acetate, and extracted four times with 70 ml each of water. Solvent was evaporated under reduced pressure, 30 ml of n-BuOH added and removed by further rotary evaporation, and the product put under vacuum over P205. This material can be purified by crystallization from warm methanol or ethanol and cooling to -20°C.
Deprotection of BOC-Asp-Asp-Asp-Bi can be performed in either order, but hydrogenolysis of the benzyl groups first has the advantage of requiring less catalyst due to the presence of the protected amino group.
Asp-Asp-Asp-Bn4 HC1: All of the above BOC-Asp-Asp-Asp-Bn4 was dissolved in 24 ml anhydrous DME and cooled in an ice bath, and 26 ml of HC1 saturated in anhydrous
dimethoxyethane (at 0°C) added with stirring. At 50 min the mixture was allowed to warm to room temperature, and after 90 min solvent was removed by rotary evaporation at reduced pressure. To remove residual HC1, 30 ml of DME was added and removed by rotary
evaporation, again this was repeated, and product placed under vacuum over NaOH pellets.
Asp-Asp-Asp: All of the above Asp-Asp- Asp-Br HC1 was dissolved in 220 ml EtOH plus 6 ml DME, 6 g 10 % Pd on charcoal was added, and the reaction bubbled at atmospheric pressure and ambient temperature with vigorous stirring. The disappearance of starting material, less benzylated intermediates and appearance of toluene was monitored by the above HPLC system using ACN/0.l% TFA (53:47). By 90 min all of the peaks absorbing at 255 nm (aside from toluene) were no longer detected, and the reaction mixture was centrifuged for 15 min at 500 x g. The supernatant was decanted, catalyst washed twice with 25 ml EtOH and the combined material filtered through a 0.45 micron TFE filter. Solvent was removed from the filtrate by rotary evaporation at reduced pressure, and placed under vacuum over P205 to give 8.2 g of a golden semisolid.
BOC-Asp-Asp-Asp: Crystallized BOC-Asp-Asp-Asp-Bn3 (2.7 g) was fully dissolved in 30 ml anhydrous ethanol, 0.27 g of 10% Pd on charcoal was added, and hydrogen bubbled with stirring at ambient temperature and pressure. By 35 min all the starting material and intermediate levels of benzylation were consumed a judged by the above HPLC system using ACN/0.l% TFA (53:47), the reaction filtered through a 0.22 micron TFE filter, and washed with an additional 10
ml EtOH. Rotary evaporation at reduced pressure, and exposure to high vacuum over P205 gave 1.8 g of BOC- Asp- Asp- Asp as a colorless hygroscopic glass.
Asp-Asp-Asp: All of the above BOC-Asp-Asp-Asp was dissolved in 50 ml anhydrous DME and placed in an ice bath. To this was added with stirring 50 ml of DME freshly saturated on ice with HC1 gas. After 30 min all of the BOC protecting group had been removed as measured by the above HPLC system using ACN/0.l% TFA (1:8), and the mixture rotary evaporated at reduced pressure to a about 10 ml, whereupon the product precipitated. Unexpectedly, further product can be driven out of solution by brief warming (for example, to about 50°C), and obtained by rapid filtration while still warm. After exposure to high vacuum over both P205 and NaOH pellets, the HC1 salt of Asp- Asp-Asp is obtained as a hygroscopic powder. This material is typically greater than 90 % pure based on 230 nm absorbance area in the above HPLC system using 100 % of 0.1 mM TFA as mobile phase. It can be further purified by preparative HPLC on Kromasil Cl 8 using 0.1 mM TFA to give the TFA salt after evaporation. Triaspartic acid can be crystallized from water after adjustment to about pH 3.
1,1,1-His-Asp-Asp and 1,1,1-Ala-Asp-Asp: These compounds were synthesized by methods similar to the above, but using N“,Nim-Bis-Boc-L-histidine N-hydroxysuccinimide ester and Boc-L-alanine N-hydroxysuccinimide ester, respectively, for addition of the third residue to Asp- Asp-Bn3. In the case of Ala- Asp- Asp, catalytic hydrogenolysis of the benzyl protecting groups was performed before the final removal of BOC group.
Comparative Examples
The following studies illustrate the problem of decomposition of the constituents of several vitamin-mineral products. The dissolution studies described herein used a U.S. Pharmacopeia (USP) type 2 apparatus with 500 ml distilled ¾0 at 37 °C stirred at 50 RPM. Although some USP methods for several vitamins calls for a measurement only at 45 min, 10, 80 and 115 minutes samples were also taken and filtered through a 0.22 micron PES membrane and injected into a reversed phase HPLC system that was monitored with photodiode array and fluorescence detectors in series. Oxygen concentration was monitored with a Clarke electrode calibrated against argon and air sparged water at 37 C. The disappearance of several components was gauged against a mixture of pure standards of known concentration.
Product #la: In the case of multivitamin-mineral products the inventors found that during a dissolution study all but about 5% of the labeled amount of ascorbic acid in a commercially
available tablet designated for use by women formulated with 2 mg of copper (as CuS04) and 18 mg of iron (as ferrous fumarate) was decomposed within 45 minutes. Well before the time of the first sample at 10 minutes these tablets had already largely disintegrated. The total initial content of vitamin C in this and other products was determined by dissolution of a crushed tablet in thoroughly argon sparged 5 mM EDTA mixed with further vigorous bubbling of argon and injection of a sample filtered under argon into the HPLC system. Product la was found to contain on average 120 % of the labeled amount of 60 mg per dose (i.e., 72 mg), all of which was irreversibly destroyed by 80 minutes in the standard dissolution test (FIG. 1). Importantly, dehydroscorbate was not detected at any time. This loss of ascorbic acid was accompanied by a rapid decrease in the oxygen concentration of the aqueous dissolution medium which reached nearly 0 percent by about 10 minutes. With continued stirring by the USP paddle, 02 was slowly reintroduced after 45 minutes but did not reestablish air saturation even by 115 minutes (FIG. 2). A nearly identical product (#lb) produced by the same manufacturer, but formulated with cupric oxide instead of the cupric sulfate lost ascorbic acid more slowly at between about 0.4 % to 0.9 % per minute between the 10 and 45 minute samples. The oxygen consumption due to dissolution of this tablet containing CuO was also slower in reaching a minimum of about 10 % after about 70 minutes. The profile of ascorbate and oxygen decreases due to product #lb were very similar to those of Product #la if 2 mg of copper as CuS04 was added to the 500 ml of water prior to the tablet. The rate produced by Product #lb in the presence of 1 mg of copper (as CuS04) added to the dissolution medium was slower than with 2 mg, as was the maximum rate of oxygen consumption.
The total content of the thiamin (vitamin Bl) in the above product #la was determined using crushed tablets and was found to average about 125% higher than the 2.4 mg labeled amount. Examining the filterable thiamin during USP type 2 experiments as above showed that the amount in solution at 10 minutes was only 67 % of the total actual content on average (84% of the labeled content). This did not change significantly after 45 minutes of dissolution (FIG. 3).
The appearance of folic acid in Product #la during USP type 2 dissolution experiments was influenced by two factors. First, the great majority of the total folic acid content remained sequestered in non-filterable particulate matter. The actual final content of folic acid was determined after 150 minutes by adding sodium hydroxide to a final concentration of 25 mM, disodium EDTA to a final concentration of 5 mM, and sonicating the mixture for 5 minutes prior to 0.22 micron filtration. This indicated that the total amount of intact folic acid at 150 min was
typically about 160 % of the 0.40 mg labeled value. However, a second factor was observed in that the p-aminobenzoyl-glutamate side chain of some folic acid is also oxidatively cleaved as detected by its fluorescence on elution from the HPLC column. This was found to be about 9 % of the labeled amount of folic acid. Sampling the dissolution experiment as a function of time shows that after 10 minutes only less than about 5 % of the labeled amount folic acid appears in the filtrate. By 45 minutes this increased slightly to about 10 % of the labeled value. Thereafter, the amount in the filtrate rapidly increases, but still only up to about 40 % by 115 min. The time at which folic acid starts to appear more rapidly in solution approximately corresponds to when the dissolved oxygen begins to increase again as a result of stirring by the USP paddle. If at any time during a dissolution experiment the solids are harvested by centrifugation and treated by sonication with 25 mM NaOH/5 mM Na2EDTA, folic acid can be found in the filtrate in an amount similar to that detected at the end of a typical run at 115 min. This shows that in Product #la folic acid is sequestered in the solids and only very slowly leaches into solution. The course of folic acid release into solution is very different with Product #lb (which incorporates insoluble cupric oxide instead of soluble cupric sulfate). With these tablets the final total content of folic acid is also about 160 % of the labeled value as with #la. However, even after 10 minutes of dissolution around 55 % of the labeled value typically appears in a filtered sample, which increases to about 65 % after 45 minutes of dissolution and on average does not further increase even in a 115 minute sample.
Product #2: A multivitamin-mineral supplement tablet from a second manufacturer also designated for use by women was labeled to contain 2 mg of copper (as CuS04) and 18 mg of iron as ferrous fumarate was also examined. The total vitamin C content as determined above was on average 225 mg, i.e. 125% of the labeled amount (180 mg, 300% of the Daily Value). During USP type 2 dissolution testing as above little ascorbate was present in the 10 minute sample, but increased to a maximum in the 45 minute sample and then slowly declined. A. This maximum amount was on average about 79 % of the labeled amount, or 63 % of the actual initial content. This represents a loss of about 83 mg of ascorbic acid on average. The concentration of dissolved oxygen falls to nearly zero after only a few minutes, and (in contrast to Product #1) remained very low despite continued stirring with the USP paddle.
Product #3: A tablet from yet another manufacturer labeled to contain 150 mg (250% of the Daily Value) of vitamin C and 2 mg of copper (as amino acid complex), but no explicit iron, did not disintegrate as quickly as those from manufacturers 1 or 2. Probably as a result, many of the
nutrients did not quickly appear in solution. In particular, ascorbic acid did not reach a maximum concentration until between 45 and 80 minutes, where it was only 38% of the labeled amount. The total content of ascorbic acid in Product #3 was not determined, thus the missing 62% represents the destruction of a minimum of 93 mg of vitamin C.
Product #4: A tablet from a fourth manufacturer which contained neither any copper nor significant iron did not release much of its nutrient content by 10 minutes of dissolution: for example of the labeled amount of ascorbic acid (110 mg) only 7% was found in a sample at this time. However, the 45 minute sample showed 151% of the labeled amount which was nearly the same as measured at 80 minutes (157%). Over the course of the dissolution run dissolved oxygen slowly decreased only to about 68% of its initial value. This product which contains no transition metals did not appear to suffer from meaningful destruction of its vitamin C or its other nutrients.
The above results show the vitamin C in a multivitamin-mineral supplement can be rapidly degraded especially in the presence of copper and/or iron. The amount of the loss may be limited by the amount of dissolved oxygen present in the dissolution vessel, or in the liquid used to consume the supplement product. With water equilibrated to air at 37 C this amounts to around 90 mg (0.51 mmole). The ascorbic acid in products actually containing less than this can be completely and irreversibly destroyed, for example 100% of the U.S. Daily Value is 60 mg. For products containing substantially greater than 90 mg of vitamin C, some can remain after the oxygen is consumed, although leaving behind considerable ascorbate degradation products. In addition, as described above, other components in the vitamin-mineral product are also decomposed.
Example 1 Inclusion of small peptides containing two of more aspartic acid residues was unexpectedly found to greatly increase the amount of ascorbic acid in samples taken from typical USP type 2 dissolution experiments with multivitamin/mineral supplements. With Product #la but where 0.125 mmole tetra-sodium l,l,l-triaspartate was initially present in the 500 mL (Asp- Asp-Asp concentration = 0.25 mM, initial pH~6.5), the ascorbic acid recovered after 45 min was remarkably about 16-fold higher than with water only (FIG. 1). The rate of oxygen consumption is dramatically decreased, with about a third of the original concentration remaining even after 45 min (FIG. 2). This greatly increased stability allows more time for the intestinal absorption of this and other vitamins. In this particular experiment the molar ratio of copper (2 mg, 0.0315 mmol) to triaspartic acid peptide is about 1 :4, and the molar ratio of copper to all aspartic acid
residues is about 1 :12. The amount of thiamine present at 45 minutes increased to an average of 83 % of the actual content of these tablets (104 % of labeled content) in comparison to 67 % (84 % of labeled content) without Asp- Asp- Asp (FIG. 3). Increasing amount of peptide can further benefit the maintenance of ascorbic acid and thiamine. Folic acid release during dissolution was considerably enhanced by inclusion of 0.25 mM Asp-Asp-Asp in the medium. Product #la showed about 55 % of the labeled folic acid amount in the 10 minute sample and about 70 % in the 45 minute sample filtrates. This is similar to the results with the cupric oxide containing Product #lb in the absence of any peptide. The amount of p-aminobenzoyl-glutamate measured in the final sonicated sample decreased to half of that in the absence of the peptide. Product #la also contained caffeine. Without added Asp-Asp-Asp peptide a portion of this was oxidized over time to 1,3,7-trimethyluric acid (8-oxo-caffeine) as determined by comparison to authentic standard. In the presence of 0.25 mM Asp-Asp-Asp the extent of this oxidation was more than halved.
Example 2 USP type 2 dissolution experiments were performed on Product #lb formulated with CuO, but with either 1 or 2 mg of copper added to the water medium as CuS04 and also tetra- sodium 1,1, 1-triaspartate in concentrations varied from 0.05 to 0.5 mM. The rate of loss of ascorbic acid in the presence of 2 mg of added copper and 0.25 mM Asp- Asp- Asp was similar to that found with Product #la (which contains 2 mg of Cu as CuS04 endogenously) in the presence of 0.25 mM Asp-Asp- Asp. This shows that the effect of the Asp-Asp-Asp peptide is the same whether the soluble copper is in the dissolution medium or from the tablet itself. The concentration of Asp- Asp- Asp required for 50 % of maximal effectiveness in preventing ascorbate loss was calculated by fitting to a hyperbolic response curve to be about 0.05 mM. Thus, the maximal benefit of Asp- Asp-Asp in this experiment requires a higher mole amount than the mole amount of the copper. The results with 1 mg of copper added to the water medium as CuS04 were consistent with this finding in that a somewhat lower concentration of Asp- Asp- Asp was required for half maximal effect in preventing loss of ascorbate.
Example 3 A USP type 2 dissolution experiment was performed on Product #lb formulated with CuO, but with a Cu<l/3)Ca2-l,l,l-triaspartate/crystalline cellulose powder added to the water medium simultaneously with the tablet. The weight ratio of the Cu<i/3)Ca2-triaspartate to cellulose was 1:1, and the final concentration of copper in the medium was equivalent to 1 mg and the concentration of Asp- Asp- Asp was 0.093 mM. The profile of ascorbate loss, and
appearance of thiamine and folic acid was not significantly different from similar runs as described in Example 2 with 1 mg of copper and 0.1 mM Asp- Asp- Asp not added as a preformed calcium-copper salt. Thus, the effectiveness of Asp-Asp-Asp is not influenced by its being provided as in a cellulose matrix.
Example 4 Inclusion of tetra-sodium 1,1,1-triaspartate (1 mM) in the dissolution of product #2 increased the average recovery of thiamine at 45 minutes by 20 % over that obtained with no added peptide. The ascorbate appeared in solution more quickly in the presence of Asp-Asp- Asp, and the average recovery of ascorbic acid from product #2 (which is labeled to contain 300 % DV) at 45 minutes in these experiments was increased by 16 % in comparison to those performed without a peptide.
Example 5 A USP type 2 dissolution of Product #la was performed with 0.125 mmole trisodium l,l-diaspartate initially present in the 500 mL (Asp2 concentration = 0.25 mM, pH ~6.5). The ascorbic acid recovered after 45 min was greater than with no Asp2 but somewhat less than in the presence of 0.25 mM Asp- Asp- Asp (FIG. 1). The profile of folic acid appearance in solution was greater than without any peptide, and similar to that liberated by 0.05 mM Asp- Asp-Asp. The profile of p-aminobenzoyl-glutamate formation was suppressed in comparison to without any peptide, and similar to 0.05 mM Asp-Asp-Asp. The profile of thiamine appearance in solution was not significantly different than without peptide. The rate of oxygen consumption was less than without a peptide. Thus, while Asp2 is effective in making some vitamins more available in solution and protecting them from degradation, it is less effective per weight of peptide than Asp-Asp-Asp, even though the latter has a 46 % higher molecular weight. Simple aspartic acid ( i.e ., not formed into a peptide) provided no improvement in maintenance of ascorbic acid, or decreased the rate of oxygen consumption.
Example 6 A USP type 2 dissolution of Product #la was performed with 0.125 mmole trisodium 1,1,1-His-Asp-Asp initially present in the 500 mL (His- Asp- Asp concentration = 0.25 mM, pH ~6.5). No improvement in maintenance of ascorbate or thiamine, diminishing oxygen consumption, or oxidation of other components was observed.
Examples 7 - 11 The effectiveness of multiple aspartate peptides on preventing the
decomposition of various vitamins was examined in homogeneous solutions. Aqueous solutions of air saturated buffer, peptide, one or more vitamins, and metal salt (e.g. ferrous chloride or cupric sulfate) were combined and incubated at 37 C, unless otherwise stated. Samples were
injected into the HPLC system as a function of time and monitored by a photodiode array detector.
Example 7 The decay of 25 mM calcium 5-methyltetrahydrofolate (5-MTHF) in 10 mM HEPES pH 7.2 buffer in the presence of peptide and 150 mM cupric sulfate (added last) was measured.
In control runs without any peptide, cupric sulfate in concentrations of above 40 mM resulted in complete loss of 5-MTHF within the first two minutes of incubation. Including either tetra- sodium l,l,l-triaspartate or penta-sodium l,l,l,l-tetraaspartate increased the half-life of the 5-MTHF in a concentration dependent manner (FIG. 4); with 2 mM giving 198 and 178 minutes respectively. Thus, while in this situation Asp-Asp-Asp and Asp4 are similarly effective at a given molarity, the former due to its lower molecular weight has the advantage in terms of weight of peptide per volume. Tri-sodium 1,1-diaspartate at 2 mM gave a concentration dependent 5-MTHF half-life of 72 minutes at 2 mM. At a concentration of 0.5 mM Asp- Asp- Asp gave a half-life longer than Asp2. The stability of 5-MTHF improves somewhat with even higher concentrations of peptide; for example with 3 mM and 4 mM Asp2 its half-life increases to 87 and 100 minutes, respectively. Thus, diaspartic acid is not quite as effective under these conditions as Asp- Asp-Asp , even on a per weight basis. The dipeptides 1,1-aspartyl-glutamic acid, 1-aspartyl-glycine, and 1,1-glutamyl-aspartic acid gave a half-lives that were between 50 to 75 percent of that of Asp2 (each determined at 0.5 mM as neutral sodium salts, and 25°C).
The decomposition of 5-MTHF is slower in acidic solutions than at neutral pH, and this was found even in the presence of cupric ions. For example, at 37 C in 1 mM HC1 (as can be found in the stomach) and in the presence of 150 mM cupric sulfate the time to half decomposition of 5-MTHF was observed to be around 20 minutes (this decay curve was not well described by a lst-order decay). With 3 mM 1,1,1-triaspartic free acid also present the time to half
decomposition was increased to around 30 minutes. Thus, while this form of folate is more stable in acid, the effectiveness of this multiple aspartate peptide is less than near neutral pH.
Example 8 The decay of 25 mM calcium 5-methyltetrahydrofolate (5-MTHF) in 40 mM MES pH 6.2 buffer in 3 mM ferrous chloride (freshly prepared and added last) was measured. In the absence of a peptide a half-life of 5-MTHF decay of 25 minutes was found. In the presence of presence of 3 mM tetra-sodium 1,1,1-triaspartate no significant loss of 5-MTHF was observed for about 50 minutes, and then deceased by about 17% per hour (FIG. 5).
Example 9 The effect of cupric sulfate (150 mM) on the combination of folic acid (10 mM) and sodium ascorbate (5 mM) was examined in the following various buffers. Reactions were continuously but slow sparged with air so that oxygen would not become limiting.
In 10 mM MES pH 6.2 about 35% of the initial ascorbic acid was decomposed by 10 minutes and 90% decomposed by 26 minutes. In the presence of 3mM tetra-sodium 1,1, 1-triaspartate 35% of the ascorbate remained even by 32 minutes. In these same reactions folic acid was more than 98% decomposed by 26 minutes in the absence of multiple aspartate peptide, but 75% remained even after 82 minutes in the presence of 3 mM Asp- Asp- Asp. In 50 mM MES pH 5.5 the ascorbate was completely consumed by 26 minutes in the absence of any peptide, but this required 47 minutes in the presence of 3 mM Asp- Asp- Asp. In these same reactions folic acid was more than 85% consumed by 26 minutes, but remained constant thereafter in the absence of aspartate peptide. This indicates that the presence of ascorbate and not just oxygen and copper is involved in the decomposition of the folic acid. In the presence of 3 mM Asp- Asp- Asp at more than 50% of the folic acid was recovered even after 82 minutes of incubation.
Similar reactions were also performed in 10 mM HEPES pH 7.2 in which the ascorbate was observed to be completely lost by 21 minutes in the absence of an aspartate peptide. In the presence of 1 and 3mM 1,1,1-triaspartate (as the tetra-sodium salt) only 33% and 18% of the initial ascorbate, respectively, was lost after 2 hours.
Example 10 The effect of cupric sulfate (150 mM) on the combination of vitamin Bl 2 (10 mM cyanocobalamin), thiamine (1.5 mg/ml as HC1 salt), folic acid (10 mM) and sodium ascorbate (5 mM) was examined in 10 mM MES pH 6.2 slowly sparged with air (FIG. 6). Vitamin B 12 rapidly decreased within the first 26 minutes by about 43% in the absence of an aspartate peptide, but remained constants thereafter presumably due to concomitant depletion of ascorbate. In the presence of 3 mM 1,1,1-triaspartate (as the tetra-sodium salt) the loss of Vitamin B12 was limited to about 20% even after 2 hours. Thiamine also rapidly disappeared by 40% over the first 26 minutes and then remained constant in the absence of an aspartate peptide. However, with 3 mM Asp- Asp- Asp included only 8% was lost at 36 min. It should be clear, however, that these particular losses of vitamins do not represent all circumstances which may have more or less ascorbic acid present and different concentrations of copper and oxygen availability.
Example 11 The effect of 1,1, 1- Ala- Asp- Asp on the decay of sodium ascorbate in 10 mM HEPES pH 7.2 at 37 was compared with 1,1,1-triaspartate in the presence of 63 mM cupric sulfate
(equivalent to 2 mg of elemental copper per 500 mL). At a peptide concentration of 0.25 mM Ala-Asp-Asp the lst-order rate of ascorbate loss was almost twice as fast as Asp- Asp- Asp. This difference is somewhat offset by the -12% lower molecular weight of the former.
Example A Tetra-sodium-l,l,l-triaspartate: l,l,l-Triaspartic free acid (117 mg of 1.5 hydrate,
0.30 mmoles) was dissolved in 5.0 ml of water at ambient temperature, 4 ml of 3 M sodium hydroxide (1.2 mmoles) was added, and the mixture stirred until completely in solution of pH 6 to 7. This was rotary evaporated under reduced pressure at 38°C to a solid that was placed under high vacuum over P205 for 24 hours to give 135 mg colorless clear flakes. When left open to the atmosphere, these quickly gained 14% in weight of water and became sticky.
Example B Tetra-sodium-l,l,l-triaspartate on microcrystalline cellulose: All of the tetra-sodium- l,l,l-triaspartate from Example A was dissolved in 5 mL of water, 135 mg of microcrystalline cellulose added, and mixed. This was rotary evaporated under reduced pressure at 38°C to a white solid that was placed under high vacuum over P2O5 for 24 hours. The resulting material was crushed to pass through a 200 mesh sieve. On exposure to the atmosphere this gained 11 % in weight as water, but none the less remained free flowing.
Example C Tetra-potassium-1, 1,1-triaspartate: 1,1,1-Triaspartic free acid (117 mg of 1.5 hydrate, 0.30 mmoles) was dissolved in 5.0 ml of water at ambient temperature, 4 ml of 3 M potassium hydroxide (1.2 mmoles) was added, and the mixture stirred until completely in solution of pH 6 to 7.
Example D Calciuml 5-1, 1,1-triaspartate: 1,1,1-Triaspartic free acid (117 mg of 1.5 hydrate, 0.30 mmoles) was dissolved in 5.0 ml of water at ambient temperature, 33 mg (-0.45 mmoles) of calcium hydroxide was added, and the mixture sonicated until completely in solution of pH 6 to 7. This was rotary evaporated under reduced pressure at 38°C to give a clear solid that was placed under high vacuum over P205 for 24 hours resulting in free flowing flakes. On leaving open to the atmosphere at ambient temperature this regained -10% weight over the next several days due to uptake of water. Over the next several months the weight was found to fluctuate by a few percent with changes in ambient humidity, but remained free flowing flakes that were never sticky. On exposure to 90 % RH for 24 hours this material clumped slightly, but was easy to break up and was not sticky. Nutrient preparations containing, for example, 0.05 mmoles,
0.10 mmoles, 0.125 mmoles, 0.25 mmoles, or 0.50 mmoles of 1,1,1-triaspartate by addition of this material would also add about 3.0 mg. 6 mg, 7.5 mg, 15 mg, and 30 mg to the calcium content
from other ingredients, respectively.
Example E Magnesium 1.5 - 1 , 1 , 1-tri aspartate : This was produced in the same manner as the above calcium salt, but using magnesium hydroxide instead of calcium hydroxide. Nutrient
preparations containing, for example, 0.05 mmoles, 0.10 mmoles, 0.125 mmoles, 0.25 mmoles or 0.50 mmoles of l,l,l-triaspartate by addition of this material would also add about 1.8 mg. 3.6 mg, 4.5 mg, 9.1 mg, and 18.2 mg to the magnesium content from other ingredients, respectively.
Example F Cuprici/4-Mgi.4-l,l,l-triaspartate: Cupric sulfate-5H20 (34 mg, 0.136 mmoles) was dissolved in 0.4 ml water and 1M sodium carbonate added with rapid stirring to give between about pH 8.5 to 9.5, the mixture centrifuged, and the supemate decanted and discarded. The precipitate was resuspended in 0.5 ml ice-cold water, recentrifuged, and the second supemate discarded. To this was added 0.54 mmoles of 1,1,1-triaspartic free acid as a 60 mM aqueous solution and vortexed to a clear blue solution to which was added about 0.76 mmole of Mg(OH)2 giving after sonication a clear solution which was rotary evaporated to near dryness under reduced pressure at 34C and put under high vacuum over P2O5 to give a blue powder. Nutrient preparations containing, for example, 0.5 mg, 1 mg, or 2 mg of copper per dose or serving of this material would also add about 1.1 mg, 2.1 mg, and 4.3 mg to the magnesium content due to other ingredients, respectively, and would also add about 0.031 mmoles, 0.063 mmoles, and 0.126 mmoles of 1,1, 1-triaspartate, respectively. The triaspartate content per dose or serving can be further increased without changing the copper content by incorporation of triaspartic acid or other non-copper containing salts of triaspartic acid, for example magnesium triaspartate, calcium triaspartate and/or ferrous triaspartate.
Example G Cupric i/4-Mgl 4-l,l,l-triaspartate on microcrystalline cellulose: Cuprici/4-Mgi.4-l,l,l- triaspartate from Example F was put into 2 ml of water with sonication to give a dark blue solution, and an equal weight of USP grade microcrystalline cellulose added. After rotary evaporation to near dryness under reduced pressure at 37C and exposure to high vacuum over P205 gave a light blue free flowing powder. This material can be added to nutrient preparation as in Example F, but using twice the weight to give the same amount of copper, magnesium, and triaspartate.
Example H Cuprici/4-Cai.4-l,l,l-tri aspartate: This was made in manner similar to Example F, but using Ca(OH)2 instead of Mg(OH)2.
Example I Cupric-Ca-l,l, 1-triaspartate on microcrystaUine cellulose: This was made in manner
similar to Example G, but using Cupric-Ca-l,l,l-triaspartate instead of Cupric-Mg-l,l,l- triaspartate.
Example J Cupric2 2-l,l,l-triaspartate: Cupric sulfate-5H20 (0.15 g, 0.60 mmoles) was dissolved in 1.0 ml water and 1M sodium carbonate added to give pH 9.1, the mixture centrifuged, and the supemate decanted and discarded. The precipitate was resuspended in 0.5 ml ice-cold water, centrifuged again, and the second supemate discarded. To this was added 0.27 mmoles of 1,1,1- triaspartic free acid as a 60 mM aqueous solution, vortexed to a clear blue solution, rotary evaporated to near dryness under reduced pressure at 38C, and put under high vacuum over P205 to give blue flakes. On being left open to the atmosphere this material gained 11% weight over the following week, but remained free flowing. Nutrient preparations containing, for example, 0.5 mg, 1 mg, or 2 mg of copper per dose or serving of this material would also add about 0.0036 mmoles, 0.0072 mmoles, and 0.014 mmoles of l,l,l-triaspartate, respectively. The triaspartate content per dose or serving can be further increased without changing the copper content by incorporation of triaspartic acid or other non-copper containing salts of triaspartic acid, for example magnesium triaspartate, calcium triaspartate and/or ferrous triaspartate.
Example K Cupricu-l,l,l-triaspartate. All of the cupric2 2-l,l, 1-triaspartate from Example I was put back into solution and another 0.27 mmoles of 1,1,1-triaspartic free acid added, vortexed to a clear blue solution, rotary evaporated to near dryness under reduced pressure at 38C, and put under high vacuum over P205 to give blue-green flakes that were free flowing and initially not sticky. Let open to the atmosphere (~50 % relative humidity) this gained 6 % in weight over 3 days and became slightly sticky. On exposure to 70 to 80 % RH for another 24 hours weight gain increased to a total 10 % and the material was wet and sticky.
Example L Cupricu-l,l,l-triaspartate on microcrystalline cellulose. All of the cupric i .i -1,1,1- triaspartate from example F was to put into solution by addition of 1.0 ml of water. USP grade microcrystalline cellulose was added in an amount equal to half the initial dry weight of the cuprid i-U l-triaspartate, sonicated briefly to distribute, rotary evaporated to near dryness under reduced pressure, and put under high vacuum over P205 to give blue flakes. This material on exposure to 70 % RH for a day and then 90 % RH for an additional day gained about 10 % in weight, but did not become sticky. Nutrient preparations containing, for example, 0.5 mg, 1 mg, or 2 mg of copper per dose or serving of this material would also add about 0.0072 mmoles, 0.014 mmoles, and 0.029 mmoles of 1,1,1-triaspartate, respectively. The triaspartate content per dose or serving can be further increased without changing the copper content by incorporation of
triaspartic acid or other non-copper containing salts of triaspartic acid, for example magnesium triaspartate, calcium triaspartate and/or ferrous triaspartate.
Example M Cupric3 l-l,l, 1-triaspartate: Cupric sulfate-5H20 (0.137g, 0.55 mmoles) was dissolved in 1.0 ml water and 1M sodium carbonate added to give pH 9.1, the mixture centrifuged, and the supemate decanted and discarded. The precipitate was resuspended in 0.5 ml ice-cold water, recentrifuged, and the second supemate discarded. This was again
resuspended in 0.5 ml water and 0.172 mmoles of l,l,l-triaspartic free acid as a 60 mM aqueous solution added rapidly with vigorous vortexing and sonication. Unlike cupric-triaspartate made with a lower molar ratio of copper to peptide, unexpectedly a dark blue suspension was produced. This was centrifuged and dried under high vacuum over P2O5. On re-exposure to air this gained 11 % in weight from uptake of water. Although this material is eventually soluble in water to the extent of about 2.8 g/L at 37°C, its dissolution is surprisingly slow. Cupric peptides with slow dissolution can be especially useful for inclusion in food or multivitamin-mineral preparations.
Example N Choline-l,l,l-triaspartate. To 5.0 ml of an aqueous 60 mM solution of l,l,l-triaspartic free acid was added 0.77 ml of 20 % choline in water (1.3 mmoles) to give a solution of pH 5.1. This was rotary evaporated to near dryness under reduced pressure, and put under high vacuum over P205 to give an off white powder. On exposure to ~50 % RH, this material became a thick oil in less than 24 hours.
Example O Choline-1, 1,1-triaspartate on microcrystalline cellulose. To all of the oily choline- l,l,l-triaspartate from Example M was added 1 ml water, mixed, a weight of USP grade microcrystalline cellulose was added in an amount equal to twice the initial dry weight of the choline-1, 1,1-triaspartate, and sonicated. This was rotary evaporated to near dryness under reduced pressure at 37 C, and put under high vacuum over P205 to give an off white powder. Although this material gained weight on exposure to the atmosphere, it remained free flowing and not sticky for several months and even after 24 hours at 90 % RH.
Example P Ferrous l,l,l-triaspartate. To 133 mg of fresh iron(II) chloride 4H20 was added 3 ml of well argon sparged water, mixed with further argon bubbling, and 1.3 ml of argon sparged 1 M NaOH added to produce a light green precipitate which was quickly centrifuged. After decanting the supernatant, well argon sparged 60 mM 1,1,1-triaspartic free acid was added and briefly sonicated under argon to give a light orange solution of pH 5.4, which was rotary
evaporated at 26 C to near dryness under reduced pressure, and put under high vacuum over P205 to give light orange brown flakes. When kept open to the atmosphere this material gained 13 % in weight over several days and became dark brown due to partial oxidation to iron(III). However, material open to air via a drying tube did not change color or significantly oxidize and was still soluble in water.
Example Q A multivitamin-mineral supplement containing 0.125 mmole triaspartate (56 mg of tetrasodium triaspartate on 56 mg of microcrystalline cellulose), 2 mg of copper (as cupric sulfate), 18 mg of iron (as ferrous fumerate), calcium carbonate (300 mg as elemental calcium), caffeine, magnesium oxide, ascorbic acid, guarana seed powder, crospovidone, beta-carotene, biotin, cholecalciferol, chromium chloride, croscarmellose sodium, cyanocobalamin, d-calcium pantothenate, dl-alpha-tocopheryl acetate, fd&c blue #1 lake, fd&c red #40 lake, fd&c yellow #5 (tartrazine) lake, folic acid, hydroxypropyl methylcellulose, manganese sulfate, niacinamide, phytonadione, polyethylene glycol, pyridoxine hydrochloride, riboflavin, silicon dioxide, sodium selenite, stearic acid, thiamine mononitrate, titanium dioxide, vitamin a acetate, zinc oxide.
It should be understood that the range of compositions is not limited by this particular list. Each of the nutrients can be present in a wide range of forms (for example vitamin B 12 as
cyanocobalamin or methylcobalamin or adenosylcobalamin), and in a wide range of weights (for example, vitamin B12 from less than 1 microgram or to more than 5 mg) as is common in the art of vitamin formulation. Nutrients can be omitted from the list, or further components added.
The nature of the excipients is not to be constrained by the above list.
Example R A multivitamin-mineral supplement as in example Q but containing 0.125 mmole triaspartate (45 mg of triaspartic free acid) plus additional calcium carbonate to bring the pH closer to neutral on dissolution (about 25 mg, = 10 mg of elemental calcium).
Example S A hair shampoo containing water, sodium lauryl sulfate, sodium laureth sulfate, cocamidopropyl betaine, sodium citrate, sodium xylenesulfonate, fragrance, sodium chloride, citric acid, sodium benzoate, hydroxypropyl methylcellulose, panthenol, panthenyl ethyl ether, methylchloroisothiazolinone, methylisothiazolinone and tetra-sodium-l,l,l-triaspartate in a concentration of about 1.1 mM (-0.05% w/w).
Example T A hair conditioner containing water, cetyl alcohol, stearamidopropyl dimethylamine, stearyl alcohol, quatemium-l8, fragrance, bis-aminopropyl dimethicone, benzyl alcohol, cetearyl alcohol, hydroxypropyl guar, glyceryl stearate, citric acid, polysorbate 60, panthenol, panthenyl
ethyl ether, oleyl alcohol, methylchloroisothiazolinone, methylisothiazolinone and tetra-sodium- l,l,l-triaspartate in a concentration of about 0.05% w/w.
Example U Garbanzos beans (chick peas) containing chick peas, water, salt, and a mixture of potassium diaspartate, triaspartate, and tetraaspartate, where the total concentration of three peptides is 0.3 mM, and triaspartate is the predominant peptide.
Example V A hematinic formulation containing 110 mg iron as ferrous fumarate (611 % of the U.S. Daily Value for iron), 60 mg vitamin C as ascorbic acid (100 % DV), microcrystalline cellulose, magnesium stearate, calcium phosphate, and 100 mg of a mixture of Asp- Asp, Asp- Asp- Asp, Asp-Asp- Asp- Asp as a neutralized potassium salt (where Asp- Asp- Asp constitutes >50 mol % of the total).
Claims
1. A composition comprising: an effective amount of one or more peptides or a pharmaceutically acceptable salt thereof, wherein each peptide has two to five amino acid residues and at least two of the residues are aspartic acid residues; one or more physiologically acceptable minerals comprising at least copper and/or iron; and one or more nutrients and/or drugs sensitive to degradation by the copper and/or iron; wherein the one or more peptides do not contain histidine.
2. A composition comprising: an effective amount of one or more peptides or a pharmaceutically acceptable salt thereof, wherein each peptide has two to five amino acid residues and at least two of the residues are aspartic acid residues; one or more physiologically acceptable minerals; one or more nutrients and/or drugs sensitive to degradation or color change by said one or more minerals; wherein the effective amount of peptide is sufficient to decrease the rate of degradation of the one or more nutrients and/or of color change and/or drugs by at least 5%.
3. The composition of claim 1 wherein the effective amount of one or more peptides ranges from a concentration of 0.01 mmol to 3.0 mmol per serving size of the composition.
4. The composition of any one of claims 1-2, wherein the salt is a sodium, potassium, iron, magnesium, calcium, copper, or choline salt, or a mixture of any two or more salts thereof.
5. The composition of claim 1-2, wherein the physiologically acceptable minerals comprise copper and/or iron, and one or more of chromium, zinc and manganese.
6. The composition of any one of claims 1-5, wherein the composition is a solid composition adapted for oral or topical administration.
7. The composition of claim 6, wherein the solid composition is a powder, tablet, or
capsule, caplet, gummies, chews, effervescent, lozenge, or confectionery.
8. The composition of any one of claims 1-5, wherein the composition is a liquid
composition adapted for oral or topical administration.
9. The composition of claim 8, wherein the liquid composition is a solution, syrup, or
suspension.
10. A food comprising the composition of claim 2 wherein said one or more physiologically acceptable minerals are endogenous to the food and/or are added to the food.
11. A composition of claim 10 wherein the effective amount of the one or more peptides is a concentration of about 0.02 mM to about 6 mM.
12. The composition of any one of claims 1-11, wherein the nutrients comprise one or more of vitamins, cofactors, micronutrients, amino acids, proteins, nucleic acids, and unsaturated lipids.
13. The composition of any one of claims 1 -2, wherein the one or more peptides each
comprises the sequence Asp- Asp.
14. The composition of any one of claims 1-13, wherein the residues of at least one of the peptides that are not aspartic acid comprises at least one amino acid selected from the group consisting of Gly, Glu, Ala, Val, Leu, lie, Phe, Tyr, Lys and Arg.
15. The composition of any one of claims 1-13, wherein each of the one or more peptides has a sequence selected from the group consisting of Asp- Asp, Asp- Asp- Asp, Asp- Asp- Asp- Asp, Ala-Asp-Asp, Asp-Asp-Glu, Asp-Asp-Asp-Glu, Glu-Asp-Asp, and , Glu-Asp- Asp-Asp.
16. The composition of any one of claims 1-15, wherein the nutrients sensitive to
degradation by copper and/or iron comprise one or more of ascorbic acid, vitamin B12, biotin, vitamin A, vitamin E, vitamin K, vitamin D, thiamine, and folate.
17. The composition of any one of claims 1-16, wherein each peptide has two, three, or four amino acid residues.
18. A pharmaceutical composition comprising a pharmaceutically active ingredient and the composition of any one of claims 1-17.
19. A composition of claim 18, wherein the metal is explicitly added to the composition.
20. A composition of claim 18, wherein the metal is an impurity of other component or components of the composition.
21. A composition comprising: an effective amount of one or more peptides or a pharmaceutically acceptable salt thereof, wherein each peptide has two to five amino acid residues and at least two of the residues are aspartic acid residues; one or more physiologically acceptable minerals or other physiologically acceptable agents capable of degrading one or more nutrients or drugs; and one or more nutrients and/or drugs sensitive to degradation by the physiologically acceptable minerals or other physiologically acceptable agents; wherein the one or more peptides do not contain histidine.
22. A method for decreasing the rate of decomposition of nutrients in vitamin-mineral
products and/or drug products during ingestion and/or dissolution testing comprising incorporation of an effective amount of one or more peptides or a pharmaceutically acceptable salt thereof, wherein each peptide has two to five amino acid residues and at least two of the residues are aspartic acid residues; wherein the one or more peptides do not contain histidine.
23. The method of claim 22, wherein the effective amount of one or more peptides ranges from 0.01 mmol to 3.0 mmol per serving size of the product.
24. The method of claim 22, wherein the salt is a sodium, potassium, iron, magnesium, calcium, copper, or choline salt, or a mixture of any two or more salts thereof.
25. The method of claim 22, wherein the one or more peptides each comprises the sequence
Asp- Asp.
26. A method for decreasing the rate of degradation of nutrients and/or of color in food
comprising incorporation of an effective concentration of one or more peptides or a pharmaceutically acceptable salt thereof, wherein each peptide has two to five amino acid residues and at least two of the residues are aspartic acid residues; wherein the one or more peptides do not contain histidine.
27. The method of claim 26, wherein the effective amount of peptide is sufficient to decrease the rate of degradation of the one or more nutrients and/or drugs and/or of color by at least 5%.
28. The method of claim 26, wherein the effective amount of one or more peptides ranges from a concentration of about 0.02 mM to about 6 mM.
29. The method of any of claims 26-28, wherein the salt is a sodium, potassium, magnesium, calcium, or choline salt, or a mixture of any two or more salts thereof.
30. A cosmetic or hair-care product composition comprising a topical carrier and the an
effective amount of one or more peptides or a pharmaceutically acceptable salt thereof, wherein each peptide has two to five amino acid residues and at least two of the residues are aspartic acid residues; wherein the one or more peptides do not contain histidine.
31. The composition of claim 30, wherein the one or more peptides each comprises the
sequence Asp-Asp.
32. The composition of claims 30-31 , wherein the effective amount of one or more peptides ranges from a concentration of about 0.02 mM to about 6 mM.
33. The composition of claims 30-32, wherein the effective amount of peptide is sufficient to decrease the rate of degradation of hair by at least 5%.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/770,847 US11912785B2 (en) | 2017-12-06 | 2018-12-06 | Peptide compositions for slowing degradation of vitamin mineral supplements, foods, pharmaceutical and cosmetics |
EP18886714.7A EP3720415A4 (en) | 2017-12-06 | 2018-12-06 | Peptide compositions for slowing degradation of vitamin-mineral supplements, foods, pharmaceuticals, and cosmetics |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762708364P | 2017-12-06 | 2017-12-06 | |
US62/708,364 | 2017-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019112630A1 true WO2019112630A1 (en) | 2019-06-13 |
Family
ID=66751142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/000390 WO2019112630A1 (en) | 2017-12-06 | 2018-12-06 | Peptide compositions for slowing degradation of vitamin-mineral supplements, foods, pharmaceuticals, and cosmetics |
Country Status (3)
Country | Link |
---|---|
US (1) | US11912785B2 (en) |
EP (1) | EP3720415A4 (en) |
WO (1) | WO2019112630A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999050286A2 (en) * | 1998-03-31 | 1999-10-07 | University Of Cincinnati | Antioxidant peptides derived from apolipoprotein a-iv |
US20030129194A1 (en) * | 1997-02-13 | 2003-07-10 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin D compounds |
US20040180102A1 (en) * | 2002-07-31 | 2004-09-16 | Procyte Corporation | Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto |
WO2010037553A1 (en) * | 2008-10-03 | 2010-04-08 | Lipotec S.A. | Peptides useful in the treatment and/or care of skin, mucous membranes, scalp and/or hair and their use in cosmetic or pharmaceutical compositions |
EP2266590A2 (en) * | 2002-02-22 | 2010-12-29 | Shire LLC | Active agent delivery sytems and methods for protecting and administering active agents |
US20110027209A1 (en) * | 2008-04-08 | 2011-02-03 | Merck Patent Gesellschaft | Compositions Containing Cyclic Peptides And Methods Of Use |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4171299A (en) * | 1975-04-04 | 1979-10-16 | The Regents Of The University Of California | Polypeptide agents for blocking the human allergic response |
MX3790E (en) | 1975-04-04 | 1981-07-20 | Univ California | METHOD FOR THE PREPARATION OF POLYPEPTIDE DERIVATIVES |
US4863898A (en) * | 1986-02-06 | 1989-09-05 | Albion International, Inc. | Amino acid chelated compositions for delivery to specific biological tissue sites |
US7060708B2 (en) * | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US20020110632A1 (en) | 2000-09-29 | 2002-08-15 | The Procter & Gamble Co. | Beverage compositions comprising arabinogalactan and defined vitamins |
US6426424B1 (en) | 2000-10-11 | 2002-07-30 | Albion International, Inc. | Composition and method for preparing granular amino acid chelates and complexes |
US20060013892A1 (en) | 2001-11-28 | 2006-01-19 | Albion International Inc. | Administration of amino acid chelates for reduction in alcohol dependency |
US7994217B2 (en) | 2002-05-02 | 2011-08-09 | Xanodyne Pharmaceuticals, Inc. | Prenatal multivitamin/multimineral supplement |
AU2003302660A1 (en) | 2002-12-05 | 2004-06-23 | Md Bioalpha Co., Ltd. | Method for preparation of amino acid chelate |
JP2007217358A (en) | 2006-02-17 | 2007-08-30 | Nippon Meat Packers Inc | Anti-oxidizing peptide |
US20080096804A1 (en) | 2006-10-20 | 2008-04-24 | Viva Pharmaceuticals Inc. | Pure amino acid chelate complexes and uses thereof |
US20100215768A1 (en) | 2009-02-24 | 2010-08-26 | Pero Ronald W | Nutritional supplement |
GB201409145D0 (en) * | 2014-05-22 | 2014-07-09 | Univ Strathclyde | Stable emulsions |
CN104177477A (en) | 2014-08-28 | 2014-12-03 | 滨州万嘉生物科技有限公司 | Fish anti-oxidation active peptide and preparation method thereof |
-
2018
- 2018-12-06 WO PCT/US2018/000390 patent/WO2019112630A1/en unknown
- 2018-12-06 EP EP18886714.7A patent/EP3720415A4/en active Pending
- 2018-12-06 US US16/770,847 patent/US11912785B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030129194A1 (en) * | 1997-02-13 | 2003-07-10 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin D compounds |
WO1999050286A2 (en) * | 1998-03-31 | 1999-10-07 | University Of Cincinnati | Antioxidant peptides derived from apolipoprotein a-iv |
EP2266590A2 (en) * | 2002-02-22 | 2010-12-29 | Shire LLC | Active agent delivery sytems and methods for protecting and administering active agents |
US20040180102A1 (en) * | 2002-07-31 | 2004-09-16 | Procyte Corporation | Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto |
US20110027209A1 (en) * | 2008-04-08 | 2011-02-03 | Merck Patent Gesellschaft | Compositions Containing Cyclic Peptides And Methods Of Use |
WO2010037553A1 (en) * | 2008-10-03 | 2010-04-08 | Lipotec S.A. | Peptides useful in the treatment and/or care of skin, mucous membranes, scalp and/or hair and their use in cosmetic or pharmaceutical compositions |
Non-Patent Citations (1)
Title |
---|
See also references of EP3720415A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP3720415A1 (en) | 2020-10-14 |
US11912785B2 (en) | 2024-02-27 |
EP3720415A4 (en) | 2021-11-24 |
US20200392180A1 (en) | 2020-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9283263B2 (en) | Compositions and methods for enhancing recovery after surgery or an athletic performance | |
US20070088086A1 (en) | Method of using synthetic L-Se-methylselenocysteine as a nutriceutical and a method of its synthesis | |
ZA200600203B (en) | Multivitamin syrup for children or young adults | |
US9597308B2 (en) | N-acetyl L-cysteine chelates and methods for making and using the same | |
JP2019147820A (en) | Metabolism activator | |
US11912785B2 (en) | Peptide compositions for slowing degradation of vitamin mineral supplements, foods, pharmaceutical and cosmetics | |
JP4814501B2 (en) | Antioxidant function improver | |
JP2011116761A (en) | Antioxidative peptide derived from royal jelly | |
JP2005263782A (en) | Antioxidative peptide derived from royal jelly | |
JPH10262610A (en) | New calcium composition | |
EP1205471A1 (en) | A method of using synthetic L-SE-Methylselenocysteine as a nutriceutical and a method of its synthesis | |
JP2001114800A (en) | Peptide for reducing cholesterol | |
WO2022224776A1 (en) | Lipid decrease promoter | |
CA2922396C (en) | N-acetyl l-cysteine chelates and methods for making and using the same | |
BR102018071692A2 (en) | Process for Obtaining a Microparticle Containing High Bioavailability, Microparticle Effect and Uses of the Microparticle | |
Rivière et al. | Plant kingdom as source of vitamins | |
CA3041914C (en) | Anaerobic antioxidant composition | |
EP3733197A1 (en) | Anaerobic antioxidant composition | |
WO2023157025A1 (en) | Novel pharmaceutical or nutraceutical composition for treating or preventing epilepsy | |
AU2023203576A1 (en) | Anaerobic antioxidant composition | |
JPH07308166A (en) | Active oxygen scavenging food | |
RO137742A0 (en) | Innovative formula of an orally administered product with complex composition based on hyaluronic acid and astaxanthin with photoprotective, antioxidant and antiage role - food supplement | |
JP2003238590A (en) | Hypocholesterolemic peptide | |
EVENSON | MARILYN A. SWANSON |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18886714 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018886714 Country of ref document: EP Effective date: 20200706 |